

Annual  
Consolidated  
*Financial Report*  
2022/2023



## Avant Mutual Group Limited ABN 58 123 154 898

*(A company limited by guarantee)*

### Table of contents

Directors' report	1
Auditor's independence declaration	7
Consolidated statement of comprehensive income	8
Consolidated statement of financial position	9
Consolidated statement of changes in equity	10
Consolidated statement of cash flows	11
Notes to the financial statements:	
Note 1 About this report	12
Note 2 Reconciliation of profit after income tax to net cash flows from operating activities	15
Note 3 Investing activities	16
Note 4 Underwriting activities	20
Note 5 Other operating activities	33
Note 6 Financial risk management	39
Note 7 Capital management	45
Note 8 Income tax	48
Note 9 Property and equipment	51
Note 10 Intangible assets	53
Note 11 Equity	55
Note 12 Remuneration of key management personnel	57
Note 13 Remuneration of auditors	58
Note 14 Events occurring after the reporting period	59
Note 15 Contingent liabilities	59
Note 16 Summarised company financial information	60
Note 17 Investments in controlled entities	61
Note 18 Related parties	63
Directors' declaration	64
Independent auditor's report	65

# Directors' report

## 30 June 2023

### Directors' report

The Directors present their report on the Group consisting of Avant Mutual Group Limited (the Company) and the entities it controlled at the end of, or during, the financial year ended 30 June 2023 (the Group).

#### Directors

The following persons were Directors of the Company during the financial year ended 30 June 2023 and up to the date of this report:

- Dr Beverley Rowbotham AO (Chair)
- Mr Peter Beck
- Dr Jan Dudley AM
- Dr Gillian Farrell
- Dr William Glasson AO
- Dr Steven Hambleton AM
- Mr Peter Polson
- Mr Duncan West
- Dr Douglas Travis (resigned 16 November 2022)
- Dr Penelope Browne (appointed 16 November 2022)

#### Principal activities

The principal activities of the Group during the year consisted of the protection, support and safeguarding of the reputation and interests of its members and policyholders and which included, through its wholly-owned entity, Avant Group Holdings Limited (AGHL), managing the investment activities of the Company's capital reserves and acting as the holding company for the Group's subsidiaries which included:

- Avant Insurance Limited (AIL), of an insurer for the professional indemnity risks of the members of the Company. This involves underwriting medical and health malpractice and legal expenses insurance policies. AIL also distributes business insurance products and undertakes investment activities related to its insurance activities.
- The Doctors' Health Fund Pty Ltd (DHF), provided doctors and the medical community, their employees and families and Avant employees with access to the market-leading suite of health insurance products.
- Darjack Pty Ltd (Cgov), provided technology solutions that allow efficient credentialing processes in the healthcare industry
- KA JV Pty Ltd (Kooyong) provided lending solutions.
- MyPracticeManual Pty Ltd (MPM) provided an online practice management platform that integrates best practice policies and procedures, task management, a secure document management system including a templates library, personalised training and compliance modules and customisable registers.
- HMPM Pty Ltd (trading as HMPM or Hoxton), provided consulting and outsourced services to practices and practitioners.
- Doctors Financial Services Pty Limited (DFS), provides general and personal financial advice on life insurance (death cover, TPD, trauma and income protection and business expense).
- JRB Technologies Pty Ltd (trading as myBeepr) provided a software platform for health professionals and administrators to communicate.
- Avant Law Pty Ltd, provided legal services.
- Avant Services Co. Pty Ltd provided internal services.

The Group also includes an associate, Team Medical Supplies Pty Ltd, a medical supplies business.

#### Dividends paid or recommended

During the year, the Board declared dividends under the Retirement Reward Plan ("RRP") totalling \$14,400,000 (2022: \$11,100,000) to eligible retiring members. These were the dividends determined under the RRP, and this marked the eighth time the Board has determined to pay franked dividends to members.

# Directors' report

## 30 June 2023

### Directors' report (continued)

#### Review of operations

The Group's result for the financial year ended 30 June 2023 is a net profit after tax of \$96,700,000 (2022: net loss after tax of \$48,100,000). The total members' accumulated equity as at 30 June 2023 is \$1,395,600 (2022: \$1,317,500,000).

#### Retirement Reward Plan

The Company is proud of its Retirement Reward Plan which rewards eligible members for their loyalty to the Group by way of a dividend upon permanent retirement from medical practice.

During the year the Company resolved to notionally contribute an additional \$30,000,000 (2022: \$28,100,000) to the RRP with respect to the year ended 30 June 2023. This brings the total assets notionally allocated to the RRP of \$405,300,000 (2022: \$382,900,000).

#### Matters subsequent to the end of the financial year

##### Retirement Reward Plan

Having considered the financial position and projected outlook for Avant, the Board resolved to notionally contribute a further \$30,000,000 to the RRP in respect of the year ended 30 June 2023.

In addition, at that meeting, the Board also resolved to determine dividends and authorise payments for Retirement Reward Dividends totalling \$15,800,000 (2022: \$14,400,000) to eligible retiring members. These are the ninth time dividends were determined under the RRP, and this continues the tradition of being the first medical defence organisation in Australia to pay fully franked dividends to its members.

##### *myBeepr*

Prior to 30 June 2023 the Board made a decision to cease further investment into myBeepr. Subsequent to the end of the year, processes commenced for the orderly wind down for an expected immaterial cost to the Group.

Other than that described above, no other matter or circumstance has arisen since 30 June 2023 that has significantly affected or may significantly affect:

- i. the operations of the Group in future financial years, or
- ii. the results of those operations in future financial years, or
- iii. the state of affairs of the Group in future financial years.

#### Significant changes in the state of affairs

In the opinion of the Directors, other than described above, there were no significant changes in the state of affairs of the Group that occurred during the financial year ended 30 June 2023.

#### Likely developments and expected results of operations

Further information on likely developments in the operations of the Group and the expected results of operations, have not been included in this report because the Directors believe it would be likely to result in unreasonable prejudice to the Group.

#### Environmental regulation

The Group is not subject to any significant environmental regulation in respect of its activities.

# Directors' report

30 June 2023

## Directors' report (continued)

### Information on Directors

#### Dr Beverley Rowbotham AO, MBBS (Hons 1) MD, FRACP, FRCPA, FAICD

**Experience and expertise** Dr Rowbotham was elected the Chair of Avant Mutual in July 2019 and is a Director of several Group subsidiaries. She is a clinical and laboratory haematologist and was awarded Officer of the Order of Australia in 2019 for her distinguished service to medicine through roles with professional associations, to pathology and to medical education. She chairs the Australian Government's National Pathology Accreditation Advisory Council. Dr Rowbotham is Associate Professor at the University of Queensland and is a Fellow of the Australian Institute of Company Directors.

**Avant Directorships** Dr Rowbotham is the Chair of Avant Mutual Group Limited and Avant Group Holdings Limited and is a Director of Avant Insurance Limited, The Doctors' Health Fund Pty Ltd, Medical Defence Association of Victoria Limited, The Medical Defence Union Pty Limited, United Medical Protection Pty Limited and the Avant Foundation Limited. Dr Rowbotham is also Chair of the Group Nominations Committee and a Member of the Group Remuneration Committee, DHF Remuneration Committee, DHF Risk Committee, DHF Audit Committee and New Ventures Advisory Committee.

#### Mr Peter Beck BSc, FIA, FIAA, FSA, FASFA

**Experience and expertise** Mr Beck is an actuary by profession and has over 40 years' experience in banking, insurance, superannuation and investments working in Australia, New Zealand, Asia, South Africa and the United Kingdom. He was formerly CEO of Pillar Administration, CEO of CommInsure, and Group General Manager, Strategic Development and Group Appointed Actuary at Colonial. Mr Beck is also a director of QInsure.

**Avant Directorships** Mr Beck is a Director of Avant Mutual Group Limited, Avant Group Holdings Limited, Avant Insurance Limited, Chair of The Doctors' Health Fund Pty Ltd, Group Risk Committee and Group Audit Committee and a Member of the Group Investment Committee and the DHF Remuneration Committee.

#### Dr Penny Browne MBBS, Dip Obst RCOG, FRACGP, MHL, GAICD

**Experience and expertise** Dr Browne is a General Practitioner, General Practitioner supervisor and senior staff specialist at the Hornsby-Brooklyn GP unit, NSW. Dr Browne has significant governance experience and is currently a non-executive director for Doctors Health Advisory Service NSW. She has extensive medico legal experience as was formerly the inaugural chief medical officer at Avant. Dr Browne is a graduate of the Australian Institute of Company Directors.

**Avant Directorships** Dr Browne is a Director of Avant Mutual Group Limited and Avant Group Holdings Limited and a Member of the Group Risk Committee and the Group Audit Committee.

#### Dr Jan Dudley MBBS, FRANZCOG, GAICD

**Experience and expertise** Dr Dudley is a VMO Obstetrician and Gynaecologist, with over 35 years' experience working in NSW Health across tertiary public and private hospitals. Dr Dudley was awarded an OAM in 2021 for services to Obstetrics and Gynaecology. Dr Dudley has significant governance experience at a local hospital level and was a longstanding member of Avant's NSW Medical Experts committee. Dr Dudley was elected on to the Avant Board in 2014 and has served on Nominations and Remuneration, Investment and Audit and Risk subcommittees, as well as the NASC. Dr Dudley is also an appointed Director of SESLHD. Dr Dudley is a graduate of the Australian Institute of Company Directors.

**Avant Directorships** Dr Dudley is a Director of Avant Mutual Group Limited, Avant Group Holdings Limited, Avant Insurance Limited and a Member of the Group Risk Committee, Group Audit Committee and Group Investment Committee.

# Directors' report

30 June 2023

## Directors' report (continued)

### Information on Directors

<b>Dr Gillian Farrell</b> MBBS, FRACS	
<b>Experience and expertise</b>	Associate Professor Dr Farrell is a plastic and reconstructive surgeon who works as a Senior Oncological Surgeon at Peter MacCallum Cancer Centre and is the Head of the Plastic Surgery Unit at Royal Darwin Hospital. She is the ASPS Clinical Lead of the Australian Breast Device Registry, a member of TGA Breast Implant Expert Working Group, and the Australian Access to Breast Reconstruction Collaborative Group. She is an Associate Professor in the Department of Public Health and Preventative Medicine, Monash University.
<b>Avant Directorships</b>	Dr Farrell is a Director of the Company, Avant Group Holdings Limited, The Doctors' Health Fund Pty Ltd and a Member of the DHF Audit Committee and DHF Risk Committee.
<b>Dr William Glasson AO</b> , MBBS (UQ), FRANZCO, FRACS, FRACGP, FRCOphth, DipAppSc (Opt), GAICD	
<b>Experience and expertise</b>	Dr Glasson is a practicing Ophthalmologist working in urban, rural and regional Australia as well as in East Timor. Dr Glasson is the former Federal President of the Australian Medical Association (AMA) and was awarded the Gold Medal for his services in 2017. As AMA President he led the AMA Presidential Medical Indemnity Taskforce during the medical indemnity crisis of 2005. Dr Glasson is also a former President of the Royal Australian and New Zealand College of Ophthalmologists. He has been awarded an Order of Australia for his services to rural and regional medicine. Dr Glasson has significant skills and knowledge in finance, management and governance. He is a director of Institute of Urban and Indigenous Health, Anglican Grammar School Board, Fresenius Medical Care Day Hospitals and the Ophthalmic Research Institute of Australia. He is a past member of Cancer Australia Advisory Committee.
<b>Avant Directorships</b>	Dr Glasson is a Director of Avant Mutual Group Limited and Avant Group Holdings Limited, and a Member of the Group Risk Committee and Group Audit Committee.
<b>Dr Steven Hambleton AM</b> MBBS, FAMA, FRACGP (Hon), FAICD	
<b>Experience and expertise</b>	Dr Hambleton is a Specialist General Practitioner and former Federal President of the AMA. He is currently the Chief Clinical Advisor for the Australian Digital Health Agency and serves on the boards of the Digital Health CRC and Mercy Community Services.
<b>Avant Directorships</b>	Dr Hambleton is a Director of Avant Mutual Group Limited and Avant Group Holdings Limited, and a Member of the Group Investment Committee, Group Remuneration Committee, and Group Nominations Committee.
<b>Mr Peter Polson</b> BCom, MBL, PMD	
<b>Experience and expertise</b>	Mr Polson has an extensive background in banking, insurance and financial services. He was formerly Managing Director of Colonial First State Investments and the Commonwealth Bank Group as Group Executive responsible for all Investment and Insurance Services. Mr Polson is the Chair of IDP Education Limited and Very Special Kids. He is currently a director of several entities at the Copia group.
<b>Avant Directorships</b>	Mr Polson is a Director of Avant Mutual Group Limited, Avant Group Holdings Limited and Avant Insurance Limited (Chair), Chair of the Group Investment Committee and New Ventures Advisory Committee and a Member of the Group Remuneration Committee and Group Nominations Committee.
<b>Mr Duncan West ANZIIIF (Snr Assoc.)</b> , CIP, FCII, BSc (Econ), GAICD	
<b>Experience and expertise</b>	Mr West has over 35 years' experience in general and life insurance. He has worked in the UK, India and Australia including as CEO of Vero Insurance and CGU Insurance. Mr West holds a Graduate Diploma in Business, and a Bachelor of Science in Economics. He is a Senior Associate of the Australia and New Zealand Institute of Insurance and Finance and an honorary life member. Mr West is Chair of Habitat for Humanity Australia, Challenger Limited and Challenger Life Company Limited and a Non-Executive Director of Suncorp Group Limited and Helia Group Limited.
<b>Avant Directorships</b>	Mr West is a Director of Avant Mutual Group Limited, Avant Group Holdings Limited, Avant Insurance Limited and The Doctors' Health Fund Pty Ltd, Chair of the Group Remuneration Committee and DHF Remuneration Committee and a Member of the Group Nominations Committee and New Ventures Advisory Committee.

# Directors' report

30 June 2023

## Directors' report (continued)

### Meetings of Directors

The number of meetings of the Company's Board of Directors and of each Board committee held during the year ended 30 June 2023, and the number of meetings attended by each Director are set out in the tables below.

Directors' attendance	Avant Mutual Group Board		Group Audit Committee		Group Risk Committee	
	Full meeting		Full meeting		Full meeting	
	A	B	A	B	A	B
Dr Beverley Rowbotham AO	8(c)	8	*	*	*	*
Mr Peter Beck	8	8	5(c)	5	6(c)	6
Dr Jan Dudley	8	8	4	5	5	6
Dr Gillian Farrell	7	7	*	*	*	*
Dr William Glasson AO	8	8	2	2	2	2
Dr Steven Hambleton AM	7	8	2	3	2	4
Mr Peter Polson	8	8	*	*	*	*
Mr Duncan West	8	8	3	3	4	4
Mr Douglas Travis (resigned 16/11/2022)	3	4	2	3	3	4
Dr Penny Browne (appointed 16/11/2022)	3	4	2	2	2	2

A = Number of meetings attended

B = Number of meetings held and required to attend in the year during the period the Director held office or was a member of the relevant Committee.

(c) = Chair of relevant Board/Committee

\* = Not a member of the relevant Committee

Directors' attendance	Group Investment Committee		Group Remuneration Committee		Group Nominations Committee	
	Full meeting		Full meeting		Full meeting	
	A	B	A	B	A	B
Dr Beverley Rowbotham AO	*	*	5	5	2(c)	2(c)
Mr Peter Beck	4	4	*	*	*	*
Dr Jan Dudley	4	4	*	*	*	*
Dr Gillian Farrell	*	*	*	*	*	*
Dr William Glasson AO	*	*	3	3	1	1
Dr Steven Hambleton AM	4	4	2	2	1	1
Mr Peter Polson	4(c)	4(c)	5	5	2	2
Mr Duncan West	*	*	5(c)	5(c)	2	2
Mr Douglas Travis (resigned 16/11/2022)	*	*	*	*	*	*
Dr Penny Browne (appointed 16/11/2022)	*	*	*	*	*	*

A = Number of meetings attended

B = Number of meetings held in the year during the period the Director held office or was a member of the relevant Committee.

(c) = Chair of relevant Board/Committee

\* = Not a member of the relevant Committee

## Directors' report

30 June 2023

### Directors' report (continued)

#### Company Secretary

The following persons were Company Secretaries of the Company during the financial year ended 30 June 2023 and up to the date of this report (unless otherwise stated):

- Mrs Zana Jordan
- Mr Patrick Esplin (resigned 30 May 2023)
- Mrs Natalie Young (appointed 30 May 2023)

#### Proceedings on behalf of the Company

No person has applied to the Court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party, for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

No proceedings have been brought or intervened in on behalf of the Company with leave of the Court under section 237 of the *Corporations Act 2001*.

#### Insurance of officers

During the financial year the Company paid a premium to insure directors and officers in respect of liabilities and legal costs of defending claims during their tenure in managing the Group and its controlled entities.

Under the terms of the insurance contract, the premium paid and the nature of the cover provided are required to be kept confidential.

#### Auditor

Deloitte Touche Tohmatsu continues in office in accordance with section 327 of the *Corporations Act 2001*(Cth).

#### Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 7.

#### Rounding of amounts

In accordance with *ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191*, all amounts have been rounded to the nearest million dollars, except where indicated. Any discrepancies between total and sums of components in tables contained in this report are due to rounding.

This report is made in accordance with a resolution of the Board of Directors.



**Dr Beverley Rowbotham AO**

Chair  
Sydney  
5 September 2023



Deloitte Touche Tohmatsu  
ABN 74 490 121 060  
Quay Quarter Tower  
50 Bridge Street  
Sydney, NSW 2000  
Australia

Tel: +61 2 9322 7000  
www.deloitte.com.au

5 September 2023

Board of Directors  
Avant Mutual Group Limited  
Darling Park Tower 3, Level 6  
201 Sussex St  
Sydney NSW 2000

Dear Board Members

**Auditor's Independence Declaration to Avant Mutual Group Limited**

In accordance with section 307C of the Corporations Act 2001, I am pleased to provide the following declaration of independence to the Board of Directors of Avant Mutual Group Limited.

As lead audit partner for the audit of the financial report of Avant Mutual Group Limited for the year ended 30 June 2023, I declare that to the best of my knowledge and belief, there have been no contraventions of:

- The auditor independence requirements of the Corporations Act 2001 in relation to the audit; and
- Any applicable code of professional conduct in relation to the audit.

Yours faithfully

A handwritten signature in black ink, appearing to read "Stuart Alexander".

DELOITTE TOUCHE TOHMATSU

A handwritten signature in black ink, appearing to read "Stuart Alexander".

Stuart Alexander  
Partner  
Chartered Accountants

# Consolidated statement of comprehensive income

## For the year ended 30 June 2023

	Note	2023 \$'million	2022 \$'million
Gross written premium	4(a)	452.6	430.6
Member giveback		(11.8)	(5.1)
Unearned premium movement	4(a)	3.9	(11.2)
Gross earned premium		444.7	414.3
Outward reinsurance premium expense		(10.3)	(7.1)
Net earned premium (a)		434.4	407.2
Gross claims expense	4(b)	(406.6)	(356.4)
Reinsurance and other recoveries revenue	4(b)	69.4	61.2
Net claims incurred (b)	4(b)	(337.2)	(295.2)
Acquisition costs	4(i)	(40.2)	(39.3)
Other underwriting expenses	4(i)	(44.9)	(41.4)
Run-off Cover Scheme (ROCS) levy		(12.7)	(11.8)
Underwriting expenses (c)		(97.8)	(92.5)
<b>Underwriting result (a) + (b) + (c)</b>		<b>(0.6)</b>	<b>19.5</b>
Investment income/(loss) – policyholders' funds	3(a)	21.7	(14.3)
Investment expenses – policyholders' funds	3(a)	(1.1)	(1.3)
Net investment income/(loss) – policyholders' funds		20.6	(15.6)
<b>Insurance income</b>		<b>20.0</b>	<b>3.9</b>
Other income	5(a)	74.1	62.3
Other operating expenses	4(i)	(94.9)	(69.0)
Net other losses		(20.8)	(6.7)
Investment income/(loss) – members' funds	3(a)	136.5	(77.3)
Investment expenses – members' funds	3(a)	(6.2)	(7.2)
Net investment income/(loss) – members' funds		130.3	(84.5)
Share of results of associate		1.4	0.8
Gain on disposal of investment in associate		-	10.8
Finance costs	5(f)	(1.2)	(0.7)
Amortisation of intangible assets	10	-	(0.5)
<b>Profit/(loss) before income tax</b>		<b>129.7</b>	<b>(76.9)</b>
Income tax (expense)/benefit	8(a)	(33.0)	28.8
<b>Profit/(loss) after income tax</b>		<b>96.7</b>	<b>(48.1)</b>
Other comprehensive income after income tax		-	-
<b>Total comprehensive income/(loss) after income tax</b>		<b>96.7</b>	<b>(48.1)</b>
<b>Total comprehensive income/(loss) for the period attributable to:</b>			
Members of Avant Mutual Group Limited		100.3	(44.3)
Non-controlling interests		(3.6)	(3.8)
<b>Total comprehensive income/(loss) after income tax</b>		<b>96.7</b>	<b>(48.1)</b>

The above consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

# Consolidated statement of financial position

## As at 30 June 2023

	Note	2023 \$'million	2022 <sup>1</sup> \$'million
<b>Assets</b>			
Cash at bank		142.5	99.6
Trade and other receivables	5(b)	120.7	145.1
Investments and derivatives	3(b)	2,059.5	2,018.0
Reinsurance and other recoveries	4(e)	281.1	269.6
Deferred expenses	4(h)	23.1	22.7
Deferred tax assets (net)	8(c)	38.6	51.0
Right-of-use lease assets	5(f)	26.7	29.4
Property and equipment	9	6.1	7.9
Intangible assets	10	15.0	8.6
<b>TOTAL ASSETS</b>		<b>2,713.3</b>	<b>2,651.9</b>
<b>Liabilities</b>			
Trade and other payables	5(c)	99.8	96.6
Derivatives	3(b)	0.6	2.9
Current tax liabilities	8(d)	2.5	26.3
Unearned income	4(g)	267.3	268.1
Insurance contract liabilities	4(d)	899.7	892.6
Lease liabilities	5(f)	29.5	33.3
Employee related provisions	5(e)	14.6	12.9
Other provisions	5(d)	3.7	1.7
<b>TOTAL LIABILITIES</b>		<b>1,317.7</b>	<b>1,334.4</b>
<b>NET ASSETS</b>		<b>1,395.6</b>	<b>1,317.5</b>
<b>Equity</b>			
Reserves	11(a)	54.6	54.6
Accumulated surpluses	11(b)	1,342.7	1,267.1
Capital and reserves attributable to members of Avant Mutual Group Limited		1,397.3	1,321.7
Non-controlling interests		(1.7)	(4.2)
<b>TOTAL EQUITY</b>		<b>1,395.6</b>	<b>1,317.5</b>

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.

<sup>1</sup> Certain amounts have been reclassified within the statement of financial position to align with the current year's presentation. The reclassification had no impact on the total net assets nor the total comprehensive income.

## Consolidated statement of changes in equity

### For the year ended 30 June 2023

Attributable to the members of the Group						
	Note	Reserves \$'million	Accumulated surpluses \$'million	Total \$'million	Non- controlling interests \$'million	Total \$'million
Balance as at 30 June 2021	11	54.6	1,322.5	1,377.1	(1.0)	1,376.1
Total comprehensive loss for the year		-	(44.3)	(44.3)	(3.8)	(48.1)
Non-controlling interest on acquisition of subsidiary		-	-	-	0.6	0.6
Retirement reward dividend and payments		-	(11.1)	(11.1)	-	(11.1)
<b>Balance as at 30 June 2022</b>	11	<b>54.6</b>	<b>1,267.1</b>	<b>1,321.7</b>	<b>(4.2)</b>	<b>1,317.5</b>
Total comprehensive profit for the year		-	100.3	100.3	(3.6)	96.7
Transactions with minority shareholders		-	(10.3)	(10.3)	6.1	(4.2)
Retirement reward dividend and payments		-	(14.4)	(14.4)	-	(14.4)
<b>Balance as at 30 June 2023</b>	11	<b>54.6</b>	<b>1,342.7</b>	<b>1,397.3</b>	<b>(1.7)</b>	<b>1,395.6</b>

*The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.*

# Consolidated statement of cash flows

## For the year ended 30 June 2023

	Note	2023 \$'million	2022 \$'million
<b>Cash flows from operating activities</b>			
Premium and membership income received		518.4	462.6
Reinsurance premium paid		(10.0)	(7.7)
Claims paid	4(d)	(411.3)	(367.0)
Reinsurance and other recoveries received	4(d)	57.9	58.0
Run-off Cover Scheme paid		(12.8)	(11.7)
Interest received		4.6	14.1
Subscription and other income		29.6	20.1
Income tax paid		(44.4)	(32.3)
Underwriting and administrative expenses paid		(164.6)	(149.6)
<b>Net cash outflow from operating activities</b>	<b>2</b>	<b>(32.6)</b>	<b>(13.5)</b>
<b>Cash flows from investing activities</b>			
Purchase of investments		(855.7)	(450.0)
Proceeds from sale of investments		821.1	406.0
Dividends and distributions received		140.0	61.3
Purchase of fixed assets and intangibles		(2.4)	(2.0)
Investment in subsidiaries		(6.6)	-
Proceeds from disposal of investment in associate		-	35.0
Payments for investment in associates		-	(17.1)
<b>Net cash inflows from investing activities</b>		<b>96.4</b>	<b>33.2</b>
<b>Cash flows from financing activities</b>			
Lease payments	5(f)	(7.2)	(6.4)
Sublease receipts	5(f)	0.7	0.7
Retirement reward dividend payment		(14.4)	(11.1)
<b>Net cash outflows from financing activities</b>		<b>(20.9)</b>	<b>(16.8)</b>
<b>Net movement in cash at bank</b>		<b>42.9</b>	<b>2.8</b>
Cash at bank at the beginning of the year		99.6	96.8
<b>Cash at bank at the end of the year</b>		<b>142.5</b>	<b>99.6</b>

*The above consolidated statement of cash flows should be read in conjunction with the accompanying note.*

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 1. About this report

### a) Information about the company

Avant Mutual Group Holdings Limited ("the Company") is a company limited by guarantee, incorporated in Australia under the *Corporations Act 2001*. The Company and its subsidiaries' (referred to as the Group) vision is to be the most trusted professional partner in supporting doctors throughout their lives and careers through the provision of medical indemnity, private health insurance, practice management, and other financial services.

The address of the Company's registered office and principal place of business are as follows:

Level 6 Darling Park  
Tower 3,  
201 Sussex Street,  
Sydney, NSW, Australia

The financial report was authorised for issue by the Directors on 5 September 2023.

### b) Basis of preparation

This Financial Report is a general-purpose financial report (tier 1) which:

- i. has been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) and the *Corporations Act 2001*. The financial statements are for the Group and consists of the Company and its subsidiaries. The Company is a for-profit entity for the purpose of preparing the financial statements;
- ii. has been prepared on a historical cost basis except for the measurement of:
  - a) equity and derivative financial instruments at fair value,
  - b) certain debt instruments, other than loan receivables, at fair value, and
  - c) the outstanding claims liability (other than those that are short term) at the year-end measured by discounting the outstanding claims cash flows using the prevailing risk-free interest rate.
- iii. has required the use of certain critical accounting estimates and management judgment in the process of applying the Group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where judgments and estimates are significant to the financial statements have been disclosed in the relevant notes;
- iv. includes comparative amounts;
- v. is in Australian dollars, which is the Group's functional and presentation currency; and
- vi. is presented with values rounded to the nearest million dollars, or in certain cases, to the nearest one hundred thousand dollars in accordance with *ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191*.

The consolidated financial statements of the Group incorporate those of the parent company and all entities it controlled as at 30 June 2023. Control is determined by the Group when it possesses:

- i. power over the investee,
- ii. exposure or rights to variable returns due to its involvement with the investee, and
- iii. the ability to leverage its control over the investee to influence those returns.

A list of the entities controlled by the group is provided in Note 17. In cases where an entity either commenced or ceased being under control within a financial year, their results are included from the start of control or until the control's cessation date.

In preparing the consolidated financial statements, all intercompany transactions and balances are eliminated on consolidation, including unrealised gains and losses on transactions between Group companies. Amounts reported in the financial statements of subsidiaries have been adjusted where necessary to ensure consistency with the accounting policies adopted by the Group. Profit or loss and other comprehensive income of subsidiaries acquired or disposed of during the year are recognised from the effective date of acquisition, or up to the effective date of disposal, as applicable. The Group attributes total comprehensive income or loss of subsidiaries between the owners of the parent and the non-controlling interests based on their respective ownership interests.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 1. About this report (continued)

### c) Accounting policies

The principal accounting policies adopted in the preparation of these consolidated financial statements are set out in the note to which they pertain. These policies have been consistently applied to all years presented.

i. New and amended accounting standards adopted by the Group.

New or revised accounting standards, which became effective for the annual reporting period commencing on 1 July 2022, have not affected any of the amounts recognised in the current period or any prior period.

ii. New and amended accounting standards not yet adopted by the Group.

### AASB 9: Financial Instruments

AASB 9 *Financial Instruments* (AASB 9) was issued in 2014 and replaces AASB 139 *Financial Instruments: Recognition and Measurement* (AASB 139). It revises the classification and measurement of financial instruments and introduces a new expected credit loss ("ECL") model which will replace AASB 139's incurred loss approach for measuring impairment on financial assets.

AASB 9 is effective for annual reporting periods beginning on or after 1 January 2018. As the Group is predominantly connected with insurance and met the requirements in AASB 2016-6 *Amendments to Australian Accounting Standards – Applying AASB 9 Financial Instruments with AASB 4 Insurance Contracts*, it elected to defer the adoption of AASB 9 until AASB 17.

*Insurance Contracts* is mandatorily effective for the Group for its reporting period commencing 1 July 2023.

The expected impacts on the adoption of AASB 9 are as follows:

- The Group's investments that are held to fund its insurance liabilities, are currently designated as at fair value through profit or loss on initial recognition and are subsequently measured to fair value at each reporting date, reflecting the business model applied by the Group to manage and evaluate its investment portfolio. In terms of AASB 9, the Group's business model is to fund the Group's insurance contract liabilities predominantly through managing the financial assets to realise cash flows through the sale of the assets. The adoption of AASB 9 is therefore not expected to result in a material change.
- The Group's surplus investments are managed and has its performance evaluated on a fair value basis. Such assets are neither held in a held to collect nor a held to collect and sell business model. Rather, the collection of contractual cash flows is incidental to achieving the business model's objective and, in accordance with AASB 9, these assets will be measured at fair value through profit or loss, consistent with the treatment under AASB 139. No material impact is therefore expected following the adoption of AASB 9.
- The Group's other financial instruments (i.e. receivables and payables) are held at amortised cost, the accounting treatment for which under AASB 9 does not change.
- For financial assets at amortised cost other than qualifying trade receivables, a provision for expected credit losses is recognised for the amount of expected credit losses within 12 months after the reporting date unless there is a significant increase in credit loss since initial recognition in which case an amount of expected credit losses over the expected life of the financial asset is recognised. For qualifying trade and lease receivables, the Group will adopt the simplified approach to calculate ECLs based on lifetime expected credit losses. The adoption of AASB 9 is not expected to result in a material change in this regard.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 1. About this report (continued)

### c) Accounting policies (continued)

#### AASB 17: Insurance Contracts

AASB 17 *Insurance Contracts* (AASB 17) is a new accounting standard that applies to all insurance contracts. It replaces existing accounting standards AASB 4 *Insurance Contracts* and AASB 1023 *General Insurance Contracts* (AASB 1023) applicable to the Group. It will be mandatory and effective for the Group's annual reporting periods beginning 1 July 2023. The expected impacts on the adoption of AASB 17 are as follows:

**Measurement model:** AASB 17 permits, in certain circumstances, the use of a simplified approach referred to as the 'premium allocation approach' (PAA), which is similar to the current basis on which general insurance contracts are accounted for. Avant expects to apply the PAA to its insurance contracts.

ii. New and amended accounting standards not yet adopted by the Group (continued)

**Risk adjustment:** The measurement of insurance contract liabilities is required to include a risk adjustment, which reflects the compensation required for bearing the uncertainty that arises from non-financial risk. This replaces the risk margin under AASB 1023, which represents the inherent uncertainty in the net discounted central estimate. AASB 17 requires the disclosure of the confidence level that corresponds to the risk adjustment used in the measurement of insurance contract liabilities. Avant expects to adopt an AASB 17 risk adjustment with a confidence level of 75% that is expected to be lower than the equivalent AASB 1023 risk margin confidence level of 85%.

**Discount rates:** AASB 1023 requires the net central estimate of outstanding claims to be discounted using risk-free rates. AASB 17 requires estimates of future cash flows to be discounted to reflect the time value of money, including an illiquidity premium, related to those cash flows.

**Expenses:** For groups of contracts that apply the premium allocation approach and have a coverage period of one year or less, AASB 17 provides an option to recognise any insurance acquisition costs as expenses when incurred. Avant plans to apply this option to expense acquisition costs as incurred.

**Onerous contracts:** AASB 17 requires the identification of 'groups' of onerous contracts and are, in terms of the premium allocation approach assumed not to be onerous unless facts and circumstances indicate otherwise. On transition, there are not expected to be any facts and circumstances to suggest that there are onerous contracts that are required to be separately measured.

**Deferred Claims liability:** The Deferred Claims Liability (DCL) in DHF was established in June 2020 to recognise services that policyholders were unable to obtain due to Covid-19 lockdowns and the suspension of non-urgent surgeries with the expectation that there would be a bounce back in services provided to members. Under AASB 1023, the DCL balance of \$11.8m before tax at 1 July 2022 was to be amortised to the income statement over a period aligned to the expected period of deferred claims. The DCL does not meet the definition of an insurance contract liability and hence the balance at 1 July 2022 will be derecognised on transition to AASB 17 and recognised as part of Avant's opening retained earnings.

**Presentation and disclosure:** The standard introduces changes to the presentation and disclosure of insurance line items in the financial statements, introducing new line items on the statement of comprehensive income and balance sheet and increased disclosures compared with existing reporting requirements. The new disclosures will be presented in Avant's financial statements for the year ending 30 June 2024.

**Transition:** AASB 17 will be applied retrospectively to all of Avant's insurance contracts on transition.

**Financial impact:** Based on the above and work performed to date, the impact of AASB 17 adoption on Avant's reported net assets of \$1,317.5 million as at 1 July 2022 is expected to be within a range of a \$15 to \$30 million increase, or less than 3% increase to net assets, after associated tax effects. The opening net asset impact is mainly driven by increases to net assets from:

- the application of the AASB 17 risk adjustment and higher discount rates reflecting the inclusion of the illiquidity premium;
- derecognising the DCL;
- offset by a decrease to net assets due to the derecognition of the deferred acquisition costs following Avant's adoption of the accounting policy to expense such costs as incurred.

The requirements of AASB 17 are complex and the actual impact is subject to the finalisation of key assumptions in relation to each of these components.

Other new or amended standards that are not yet effective are not expected to have a material impact on the Company in the current or future reporting periods.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 2. Reconciliation of profit after income tax to net cash inflows from operating activities

#### Overview

AASB 1054 *Australian additional disclosures* requires a reconciliation of profit and loss after income tax to cash flows from operating activities.

	2023 \$'million	2022 \$'million
<b>Profit/(loss) after income tax</b>	<b>96.7</b>	<b>(48.1)</b>
Depreciation and amortisation – property and equipment and intangibles	3.0	2.5
Depreciation of right-of-use assets	4.9	5.6
Change in fair value of investments held at fair value through profit or loss	(18.2)	170.1
Dividends and distributions received	(140.0)	(61.3)
Share of profit of associates	(1.4)	(0.8)
Write down/impairment of fixed assets, intangible assets and goodwill	4.9	3.1
Gain on disposal of investment in associate	-	(10.8)
<b>Decrease/(increase) in:</b>		
Receivables	37.6	(23.0)
Reinsurance and other recoveries	(11.5)	(3.2)
Deferred expenses	(0.4)	(2.9)
Deferred tax assets/liabilities	12.4	(59.8)
<b>Increase/(decrease) in:</b>		
Reinsurance premiums payable	-	1.4
Insurance contract liabilities	7.1	(5.5)
Current tax liabilities	(23.8)	(4.4)
Unearned income	(0.8)	13.2
Employee related and other provisions	3.7	1.3
Other operating liabilities	(6.8)	9.1
<b>Net cash outflows from operating activities</b>	<b>(32.6)</b>	<b>(13.5)</b>

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 3. Investing activities

### Overview

AASB 139 specifies how an entity should classify and measure its financial assets and liabilities. Financial assets are measured either at either amortised cost or fair value.

AASB 13 *Fair Value Measurement* requires disclosure of fair value measurements by level of the following fair value measurement hierarchy (this is required for financial assets and liabilities that are both measured at fair value and those that are measured at amortised cost, but for which the fair value is disclosed):

Level 1: Fair values determined using quoted prices (unadjusted) in active markets for identical assets or liabilities,

Level 2: Fair values using inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices), or

Level 3: Fair values using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

AASB 128 *Investments in Associates and Joint Ventures* sets out the requirements for the application of the equity method when accounting for the Group's Investments in its associate.

### How we account for the numbers

#### Investments at fair value through profit or loss (FVTPL)

##### *Measurement of investments at FVTPL*

Both at initial recognition, and subsequently at each statement of financial position date, the Group measures its investments classified as FVTPL at its fair value.

Gains or losses arising from changes in the fair value of the investments that are classified as at FVTPL, are presented in the statement of comprehensive income within investment income/(loss) in the period in which they arise. Dividend income from financial assets at FVTPL is recognised in the statement of comprehensive income when the Group's right to receive payment is established. Interest income from these financial assets is recognised in the period in which it is earned and is included in the investment income/(loss).

##### *Measurement of fair value*

The fair value of financial instruments is measured and disclosed as per the requirements of AASB 13 which uses a hierarchy of inputs for the determination of fair value. Level 1 financial instruments are those traded in active markets (such as trading securities), and fair value is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price.

The fair value of financial instruments that are not traded in an active market is determined using valuation techniques. The Group uses a variety of methods and makes assumptions that are based on market conditions existing at the end of each reporting period. Quoted market prices or dealer quotes for similar instruments are used to estimate fair value for interest rate securities and are included in level 2 of the fair value hierarchy (FVH). The Group values unlisted managed funds using pricing provided by the fund's responsible entity or management company. Other techniques, such as estimated discounted cash flows, are used to determine fair value for the remaining financial instruments. These instruments are included in level 2 of the FVH. In circumstances where a valuation technique for these instruments is based on significant unobservable inputs, such instruments are included in level 3 of the FVH.

##### *Recognition and derecognition*

Purchases and sales of financial assets are recognised on trade date – the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 3. Investing activities (continued)

### Investments in associates

An associate is an entity over which the Group has significant influence and that is neither a subsidiary nor an interest in a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies.

Investments in associates are accounted for using the equity method. Under this method, an investment in an associate is recognised initially in the consolidated statement of financial position at cost and adjusted thereafter to recognise the Group's share of the associate's profit or loss and other comprehensive income. When the Group's share of losses of an associate exceeds the Group's interest in that associate, the Group discontinues recognising its share of further losses. Additional losses are recognised only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the associate.

An investment in an associate is accounted for using the equity method from the date on which the investee becomes an associate. On acquisition of the investment in an associate, any excess of the cost of the investment over the Group's share of the net fair value of the identifiable assets and liabilities of the investee is recognised as goodwill, which is included within the carrying amount of the investment. Any excess of the Group's share of the net fair value of the identifiable assets and liabilities over the cost of the investment, after reassessment, is recognised immediately in profit or loss in the period in which the investment is acquired.

The Group discontinues the use of the equity method from the date when the investment ceases to be an associate.

When the Group changes its control over an associate resulting in the associate to be recognised as a subsidiary that was previously recognised using an equity method, the Group discontinues the use of the equity method from the date when the investment ceases to be an associate. On the change in control date of the investment in an associate, any excess of the cost of the investment over the Group's share of the net fair value of the identifiable assets and liabilities of the investee is recognised as goodwill.

When the Group entity transacts with an associate, profits or losses resulting from the transactions with the associate are recognised in the Group's consolidated financial statements to the extent of external interests in the associate.

### Impairment

The Group assesses at the end of each reporting period whether there is objective evidence that a financial asset, group of financial assets or the Group's investment in an associate is impaired. A financial asset, group of financial assets or investment in an associate is impaired and impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a 'loss event') and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.

### Critical accounting estimates and judgements

The Directors have reviewed the Group's existing financial assets in line with the requirements of AASB 139 and have assessed that all financial assets are measured at fair value through profit and loss, with the exception of the investment in its associate which is accounted using the equity method, and trade debtors and loan assets that are accounted for on an amortised cost basis.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 3. Investing activities (continued)

#### a) Investment income and expenses

	2023 \$'million	2022 \$'million
<b>Investment income</b>		
Interest income	20.6	14.1
Dividends and distributions from managed funds	119.4	64.4
	140.0	78.5
Change in the fair value of investments held at fair value through profit and loss	18.2	(170.1)
<b>Total investment income/(loss)</b>	<b>158.2</b>	<b>(91.6)</b>
Investment income/(loss) – policyholders' funds	21.7	(14.3)
Investment income/(loss) – members' funds	136.5	(77.3)
<b>Total investment income/(loss)<sup>1</sup></b>	<b>158.2</b>	<b>(91.6)</b>
Investment expenses – policyholders' funds	(1.1)	(1.3)
Investment expenses – members' funds	(6.2)	(7.2)
<b>Total investment expenses</b>	<b>(7.3)</b>	<b>(8.5)</b>

#### b) Investments

The following tables represent the Group's financial assets and liabilities measured and recognised at fair value, by level of fair value measurement hierarchy:

As at 30 June 2023	Level 1 \$'million	Level 2 \$'million	Level 3 \$'million	Total \$'million
<b>Financial assets at fair value through profit or loss</b>				
Interest rate securities	616.7	2.5	-	619.2
Managed funds	-	821.5	391.8	1,213.3
Equities	209.3	-	-	209.3
	<b>826.0</b>	<b>824.0</b>	<b>391.8</b>	<b>2,041.8</b>
<b>Investment in associates<sup>2,3</sup></b>				<b>17.7</b>
<b>Total financial assets</b>				<b>2,059.5</b>
<b>Financial liabilities held for trading</b>				
Derivatives	-	0.6	-	0.6
<b>Total financial liabilities</b>	-	0.6	-	<b>0.6</b>

<sup>1</sup>Investment income has been allocated between policyholder and member funds based on the company's internal capital allocation policy.

<sup>2</sup>A 25% interest in Team Medical Supplies Unit Trust and Team Medical Supplies Pty Ltd was acquired in December 2021.

<sup>3</sup>During the year the Group increased its interest in HMPM Pty Ltd (Hoxton) from 20% (interest in associate) to 100% and is now accounted for as a 100% subsidiary of the Group.

## Notes to the consolidated financial statements

For the year ended 30 June 2023

**Note 3. Investing activities (continued)****b) Investments (continued)**

As at 30 June 2022 <sup>1</sup>	Level 1 \$'million	Level 2 \$'million	Level 3 \$'million	Total \$'million
<b>Financial assets at fair value through profit or loss</b>				
Interest rate securities	147.9	507.3	-	655.2
Managed funds	-	1,113.5	77.2	1,190.7
Equities	149.0	-	-	149.0
Derivatives	2.6	2.6	-	5.2
	<b>299.5</b>	<b>1,623.4</b>	<b>77.2</b>	<b>2,000.1</b>
<b>Investment in associates</b>				<b>17.9</b>
<b>Total financial assets</b>				<b>2,018.0</b>
<b>Financial liabilities held for trading</b>				
Derivatives	-	2.9	-	2.9
<b>Total financial liabilities</b>	-	2.9	-	<b>2.9</b>
			<b>2023</b>	<b>2022<sup>1</sup></b>
			<b>\$'million</b>	<b>\$'million</b>
<b>Total investments net of derivative liabilities</b>				
Current investments net of derivative liabilities			297.5	225.2
Non-current investments			1,761.4	1,789.9
<b>Total investments net of derivative liabilities</b>			<b>2,058.9</b>	<b>2,015.1</b>
<b>*Details of associates</b>				
Name of associate	Principal activity	Place of incorporation and principal place of business	Proportion of ownership interest and voting rights held by the Group	
			2023	2022
Team Medical Supplies Unit Trust and Team Medical Supplies Pty Ltd <sup>2</sup>	Medical suppliers	Sydney, Australia	25%	25%
HMPM Pty Ltd <sup>3</sup>	Practice management	Sydney, Australia	100%	20%

<sup>1</sup> Certain amounts have been reclassified within the fair value hierarchy following the reclassification of certain amounts in the statement of financial position.

<sup>2</sup> A 25% interest in Team Medical Supplies Unit Trust and Team Medical Supplies Pty Ltd was acquired in December 2021.

<sup>3</sup> During the year the Group increased its interest in HMPM Pty Ltd (Hoxton) from 20% (interest in associate) to 100% and is now accounted for as a 100% subsidiary of the Group.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 4. Underwriting activities

### a) Insurance contract revenue

#### How we account for the numbers

##### Premium revenue

Premium revenue charged to policyholders excludes taxes collected on behalf of third parties. The earned portion of premiums written is recognised as revenue. Premiums are earned from the date of attachment of risk and recognised over the policy period based on time, which is considered to closely approximate the pattern of risks undertaken. The portion of premium received or receivable not earned in the statement of comprehensive income at the reporting date is recognised in the statement of financial position as an unearned premium liability.

##### *Loyalty Reward Plan*

AIL operates a loyalty reward plan to reward members of the Company for their loyalty while financial performance is strong. The loyalty reward is delivered through a reduction to premium before taxes upon renewal of the insurance policy. The loyalty reward is offset against premium revenue and is recognised over the period of insurance policy in line with premium revenue. The portion of the loyalty reward not earned in the statement of comprehensive income at the reporting date is recognised in the statement of financial position as part of the unearned premium liability.

##### *Run-off Cover Scheme*

The Medical Indemnity (Run-off Cover Support Payment) Act 2004 imposes an annual levy on medical indemnity insurers to fund the Run-off Cover Scheme (ROCS). The levy is a percentage of premiums received by the insurer during the contribution year. The levy rate applicable to AIL is 5% and its contribution year is the year ending on 31 May each year. Premium charged in relation to ROCS is included in premium written and recognised as part of premium revenue. A ROCS expense is recognised in AIL on the acceptance of the risk that results in the requirement to pay the tax. The expense is recognised on the same basis as the recognition of the earned premium.

##### *Premium Support Subsidy*

The Medical Indemnity Act 2002 establishes a Premium Support Subsidy (PSS) for policyholders whose insurance costs exceed a set proportion of their gross income. AIL is responsible for administering the subsidy and in this role it obtains details of estimated gross income to determine that portion to be collected from Medicare Australia. In subsequent years, AIL obtains actual gross income details from policyholders and either collects monies from policyholders for reimbursement to Medicare Australia, or seeks additional subsidies from Medicare Australia to be passed through to the policyholder. Amounts due to and from Medicare Australia and the policyholders are recognised in the statement of financial position.

##### *Doctors' Health Fund Premium Rebate*

The Australian Government contributes a rebate towards an eligible policyholder's premium and pays this directly to the Company and which is recognised within its premium revenue. The earned portion of premiums written is recognised as revenue. Premiums are earned from the date of attachment of risk and recognised over the policy period based on time, which is considered to closely approximate the pattern of risks undertaken. The portion of premium received or receivable not earned in the statement of comprehensive income at the reporting date, is recognised in the statement of financial position as an unearned premium liability.

##### Reinsurance service expenses

Premiums ceded to reinsurers are recognised as an expense in accordance with the pattern of reinsurance service received. Reinsurance premiums payable under adjustment clauses of the reinsurance contracts are measured at the present value of expected future payments.

## Notes to the consolidated financial statements

For the year ended 30 June 2023

**Note 4. Underwriting activities (continued)****b) Net claims incurred****Overview**

Net claims expense is provided below, split between undiscounted claims expense (insurance service expenses offset by reinsurance contract revenue) and the movement in discount on outstanding claims and reinsurance provisions.

**How we account for the numbers**

**Current period claims** increase relates to risks borne by the Group in the current financial period.

**Prior period claims** relate to a reassessment of the risks borne by the Group in all previous reporting periods. The reduction in net claims incurred for prior periods reflects a reassessment by the Group's valuation actuary of the medico-legal claims environment, including the impact of tort reforms and the prudential margin held against those claims.

	2023			2022		
	Current period \$'million	Prior periods \$'million	Total \$'million	Current period \$'million	Prior periods \$'million	Total \$'million
<b>Undiscounted claims expense:</b>						
Gross claims expense	414.3	16.6	430.9	428.8	(11.4)	417.4
Reinsurance and other recoveries	(52.6)	(24.7)	(77.3)	(67.6)	(18.2)	(85.8)
<b>Net claims expense</b>	<b>361.7</b>	<b>(8.1)</b>	<b>353.6</b>	<b>361.2</b>	<b>(29.6)</b>	<b>331.6</b>
<b>Discount movement:</b>						
Gross claims (expense)/ gain	(33.0)	8.7	(24.3)	(27.1)	(33.9)	(61.0)
Reinsurance and other recoveries/(cost)	9.4	(1.5)	7.9	9.5	15.1	24.6
<b>Net discount movement</b>	<b>(23.6)</b>	<b>7.2</b>	<b>(16.4)</b>	<b>(17.6)</b>	<b>(18.8)</b>	<b>(36.4)</b>
<b>Discounted claims expense:</b>						
Gross claims expense/(gain)	381.3	25.3	406.6	401.7	(45.3)	356.4
Reinsurance and other recoveries	(43.2)	(26.2)	(69.4)	(58.1)	(3.1)	(61.2)
<b>Net discounted claims expense/(recoveries)</b>	<b>338.1</b>	<b>(0.9)</b>	<b>337.2</b>	<b>343.6</b>	<b>(48.4)</b>	<b>295.2</b>

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 4. Underwriting activities (continued)

### c) Insurance risk

#### Overview

AASB 1023 requires that an insurance group disclose the nature and extent of insurance risks that it is exposed to and provide a sensitivity analysis for the effect on profit and loss for risk variables.

Insurance risk means risk, other than financial risk, transferred from the holder of a contract to the issuer.

Key drivers of insurance risk include concentration risk, underwriting and pricing of insurance contracts, claims payment and reserving, and reinsurance.

In accordance with Prudential Standards CPS 220 *Risk Management* and GPS 230 *Reinsurance Management* issued by APRA, the Board and senior management of the Group have developed, implemented and maintain a sound and prudent Risk Management Strategy (RMS) and a Reinsurance Management Strategy (REMS). Annually, the Board certifies to APRA that adequate strategies have been put in place to monitor those risks, that the Group has systems in place to ensure compliance with legislative and prudential requirements and that the Board has satisfied itself to the compliance with the RMS and REMS.

#### Concentration/credit risk

Credit and concentration risk exposure arises because the Group's business is exclusively sourced from health industry participants and is exposed to large losses arising from groups of claims resulting from a common dependent source (for example, a large number of claims arising from a class action related to a faulty medical procedure). This exposure is monitored on a regular basis with a formal review of potential and emerging exposure at least annually.

#### Underwriting risk

Underwriting risk is managed by appropriately setting and adjusting underwriting strategy, risk selection and pricing practices throughout the underwriting cycle.

Underwriting authority is delegated to underwriters with industry experience. Delegated authority limits reflect the seniority and experience of the underwriter and are supported by controls over the acceptance of risk for both individual and group policies.

Insurance premiums are determined on an annual basis to coincide with the renewal dates of the portfolio. Premium rating is determined with regard to type of specialisation and state of practice, level of billings and other actuarial variables. The projection of future claims costs is performed by the Appointed Actuary using the same data used to estimate the outstanding claims liability to ensure the most accurate and up to date information and claims experience are used for pricing decisions.

For DHF, the provision of private health insurance in Australia is governed by the *Private Health Insurance Act 2007* (the Act) which is premised on the principle of community rating. The community rating principle applies to the setting of Australian private health insurance premiums. In principle, the premium charged may not improperly discriminate between people. Premiums may not be set on the basis of age, gender, occupation, race, existing illness or other characteristics of a person likely to vary the need for hospital or general treatment. The principles of community rating are specified in the Act. In these circumstances, Doctors' Health Fund (DHF) adopts a prudent approach to pricing its products; a process which requires approval by the Minister for Health and Aged Care. Pricing is typically determined annually and at levels which at least cover the projected benefit payments and management expenses of operating DHF.

#### Claims payment and reserving risk

Claims payment and reserving risk includes the risks that inappropriate claims are paid and that an insufficient amount is reserved for claims incurred.

Claims management authorities are delegated to claims managers with medical and/or legal qualifications and experience. Depending on their nature and complexity, claims are managed either internally or in combination with external legal advisors and solely or in combination by legal and medical practitioners.

The Group employs the services of external actuarial firms proficient in medico-legal matters and health insurance, which assists across several areas including reserving, pricing, product development, capital management and reporting.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 4. Underwriting activities (continued)

### c) Insurance risk (continued)

#### Overview (continued)

##### Reinsurance risk

Reinsurance risk includes credit risk regarding the reinsurers the Group used.

Credit and concentration risk in relation to reinsurance recoveries is managed by having several different reinsurers participate in the reinsurance program. The credit rating of participants to the program is taken into account when placing reinsurance cover for the year and the terms of the reinsurance contracts provide for the removal of participants whose credit rating falls below the minimum standard. The current minimum rating for new participants in the reinsurance program is Standard and Poor's credit rating of A.

### Sensitivity analysis of changes to actuarial assumptions

#### How we account for the numbers

The Group conducts sensitivity analyses to quantify the exposure to risk of changes in the key underlying variables. The valuations included in the reported results are calculated using certain assumptions about these variables as disclosed in note 4(d). The movement in any key variable will impact the performance and equity of the Group. The tables below describe how a change in each assumption will affect the insurance liabilities and provide an analysis of the sensitivity of the profit/(loss) and equity to changes in these assumptions both gross and net of reinsurance.

Variable	Impact of movement in variable
Inflation and superimposed inflation rates	Outstanding claims costs make an allowance for future claims inflation. In addition to the general economic inflation rate an additional amount is superimposed to take account of non-economic inflationary factors, such as increases in court awards. Such rates of superimposed inflation are specific to the model adopted. An increase or decrease in the assumed levels of either the economic or superimposed inflation would have a corresponding impact on claims expense and equity.
Discount rates	The outstanding claims liability is calculated with reference to expected future payments. These payments are discounted to adjust for the time value of money. An increase or decrease in the assumed rate will have an opposing impact on the total claims expense and equity.

Impact of changes in key variables on the Group's statement of comprehensive income and statement of financial position is provided in the sensitivity analysis below:

	Movement in variable	Financial impact <sup>1</sup>	
		2023 \$'million	2022 \$'million
Inflation and superimposed inflation rates	100 bp +	(23.2)	(17.5)
	100 bp -	21.2	16.8
Discount rates	100 bp +	10.3	10.5
	100 bp -	(11.0)	(11.0)

<sup>1</sup> The above effects are net of the Group's *prima facie* income tax rate of 30%.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 4. Underwriting activities (continued)

### d) Insurance contract liabilities

#### Overview

The net insurance liabilities arising from the Group's activities comprise insurance contract liabilities (outstanding claims liabilities), unearned premium liability, reinsurance contract assets, other recoveries receivable, reinsurance premiums payable, a deferred claims liability (for the year ended 30 June 2022) and a liability for member giveback initiatives.

The member giveback liability in the statement of financial position comprises two amounts to be paid out to members, in line with the Group's commitment to return Covid surpluses back to the Group's members:

- Unamortised premium deferrals of \$2.8m relating to a deferral of \$3.6m for the period 1 April 2023 to 1 October 2023 and \$2.1m for the period 30 June 2022 to 1 October 2022.
- A cash giveback of \$8.2m to members to be paid to eligible members following the approval of these financial statements.

These amounts have been recognised as a liability in the statement of financial position.

#### How we account for the numbers

The provision for outstanding claims is measured as the central estimate of the present value of expected future claims payments plus a risk margin. The expected future claims payments include those in relation to claims reported but not yet paid; claims incurred but not reported (IBNR); claims incurred but not enough reported (IBNER); anticipated claims handling costs and allowances for the Risk Equalisation Special Account for health insurance outstanding claims liabilities. Claims handling costs exclude costs that can be associated directly with individual claims, such as legal and other professional fees (which are included within claim payments), but include costs that can only be indirectly associated with individual claims, such as claims administration costs.

The expected future payments are discounted to present value using the prevailing risk-free rate.

A risk margin (also referred to as a prudential margin) is applied to the discounted central estimate of outstanding claims to reflect the inherent uncertainty in the central estimate to arrive at the outstanding claims provision.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 4. Underwriting activities (continued)

### d) Insurance contract liabilities (continued)

#### Critical accounting estimates and judgements

Actuarial valuations are used to estimate the components of the net insurance liabilities. Although the most appropriate methodology, analyses and assumptions are adopted, the actuarial valuations are subject to limitations and the estimates of future costs of claims are always inherently uncertain, especially for claims which involve physical and/or mental injury.

Future costs and related recoveries depend on the outcome of events which cannot be forecast precisely, such as numbers of claims which will ultimately be lodged, expectations of claimants and their legal representatives and amounts of court awards.

The assessment of the anticipated claims liability is sensitive to several factors, including the ultimate number of claims, average claim cost, inflation rates, discount factors, and changes in the medico-legal environment.

Estimates of the IBNR liability are subject to greater uncertainty than the estimates relating to the known claims.

To mitigate the risk associated with the inherent uncertainty in the liability estimation, the Group maintains a prudential margin on its claims liabilities. Maintaining such a provision is a requirement of the industry regulator APRA. The effect of such a margin is to increase the probability that the booked liability will be adequate.

The following assumptions have been used in determining the outstanding claims liabilities:

	2023	2022
Normal inflation rate	2.5%	2.5%
Superimposed inflation	2.0-2.5%	2.0-2.5%
Average weighted discount rate	4.09%	3.19%
Average weighted term to settlement - known claims	2.9 years	3.0 years
Average weighted term to settlement - IBNR claims	5.0 years	4.9 years <sup>1</sup>
Estimated ultimate number of claims	3,332	3,381
Claims handling expense percentage	6.20 - 7.00%	6.30 - 6.80%
RESA component (private health insurance claims)	7.56%	7.54%

#### Process used to determine assumptions

##### Methodology

Claims are split into six claim groups; legal expenses claims, non-civil claims, large claims (those with an estimated cost over \$1,500,000 in June 2011 dollars), medium claims (estimate cost to have exceeded \$300,000 adjusted for inflation since June 2011 dollars), small claims and infant claims. Civil claims and infant claims are further separated into different state-based jurisdictions.

##### Inflation and discount rates

Normal inflation is based on average weekly earnings as reported by an independent economics consultancy. Superimposed inflation is modelled on past experience taking into account the general experience for bodily injury claims. The rates of future investment return assumed for discounting projected future claims payments and expenses are based on market yields on Australian Government fixed interest securities.

##### Claims handling expense

Allowance for claims handling expenses is determined by analysing historical claims handling costs.

##### Average term to settlement

The average term to settlement from the balance date of the outstanding claims liabilities is determined by reference to historical claim reporting and payment patterns.

<sup>1</sup>Comparative data has been represented to align with the current year presentation. There was no impact to other comprehensive income and the statement financial position as a result of this change.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 4. Underwriting activities (continued)

#### d) Insurance contract liabilities (continued)

##### Critical accounting estimates and judgements (continued)

###### Process used to determine assumptions (continued)

###### *Estimated ultimate number of claims*

The ultimate number of claims is based on the number of current claims and an estimate of future claims emerging from past notifications. The number of future claims emerging is estimated in the valuation using a transition probability model to project claim transitions from past notifications into claims. The number of notifications to claim transitions is estimated by applying a vector of quarterly probabilities of transitions to the number of notifications not yet emerged as a claim. Transition probabilities are selected by analysing historic notification to claim emergence experience.

###### *Risk Equalisation Special Account (RESA)*

Under the provisions of the *Private Health Insurance Act 2007*, all health insurers must participate in the RESA, which charges a levy to all health insurers, and shares a proportion of the hospital claims of all persons aged 55 years and older and those with high-cost claims between all registered health insurers. The amounts payable to and receivable from the RESA are determined by the Australian Prudential Regulation Authority (APRA) after the end of each quarter. Estimated provisions for amounts payable and receivable are recognised on an accrual basis.

To estimate the RESA component a factor of 7.56% (2022: 7.54%) was applied to the gross outstanding claims provision for hospital and medical benefits. This factor was determined as the ratio of the RESA payables to total hospital and medical benefits based on the recent experience.

###### *Deferred Claims Liability*

In March 2020 the Government announced the suspension to certain surgery procedures and social distancing measures in response to the Covid-19 pandemic. In response to COVID-19 and uncertainty on how to value the deferred claims liability (DCL), in June 2020 APRA issued prescriptive guidance on how it should be assessed for prudential purposes. As data emerged on the impact of the pandemic, and valuation techniques have evolved, APRA progressively relaxed its guidance and moved to a principles-based approach. This placed greater reliance on insurers to manage their specific risks and to calculate their DCL.

The DCL balance of \$11.8 million at 30 June 2022 was to be amortised to the income statement over a period aligned to the expected delay in claims. Given the post Covid-19 claims experience has returned to normal, the unamortised balance at 30 June 2023 of \$5.6 million has been released to the income statement. In line with the Company's commitment to return Covid surpluses back to the Company's members a member giveback of \$8.2 million has been provided for as part of the Company's liabilities at 30 June 2023 and will be paid to members following the approval of these financial statements. This member giveback is in addition to the deferral of annual price rises that also occurred during the year.

## Notes to the consolidated financial statements

For the year ended 30 June 2023

**Note 4. Underwriting activities (continued)****d) Insurance contract liabilities (continued)**

	2023 \$'million	2022 \$'million
<b>Insurance contract liabilities</b>		
Central estimate	812.6	767.9
Discount to present value	(93.4)	(72.8)
Discounted central estimate	719.2	695.1
Risk margin discounted	169.5	180.6
<b>Gross outstanding discounted claims liabilities</b>	<b>888.7</b>	<b>875.7</b>
<b>Other insurance liabilities</b>		
Member giveback liability	11.0	5.1
Deferred claims liability (DCL)	-	11.8
<b>Other insurance liabilities</b>	<b>11.0</b>	<b>16.9</b>
Current insurance contract liabilities	262.7	222.1
Non-current insurance contract liabilities	637.0	670.5
	<b>899.7</b>	<b>892.6</b>
Gross claims outstanding undiscounted central estimate	812.6	779.7
Risk margin undiscounted	195.0	202.5
<b>Total gross claims undiscounted</b>	<b>1,007.6</b>	<b>982.2</b>

The following table reconciles the opening to closing balance of the insurance contract liabilities:

	2023			2022		
	Gross \$'million	Reinsurance \$'million	Net \$'million	Gross \$'million	Reinsurance \$'million	Net \$'million
Opening balance	892.6	(269.6)	623.0	898.1	(266.4)	631.7
Current year claims expense/(recovery)	381.3	(43.2)	338.1	401.7	(58.1)	343.6
Prior year claims development	25.3	(26.2)	(0.9)	(45.3)	(3.1)	(48.4)
(Claim payments)/recoveries during the year	(411.3)	57.9	(353.4)	(367.0)	58.0	(309.0)
Gross earned premium - member giveback	11.8	-	11.8	5.1	-	5.1
<b>Closing balance</b>	<b>899.7</b>	<b>(281.1)</b>	<b>618.6</b>	<b>892.6</b>	<b>(269.6)</b>	<b>623.0</b>

**Risk margin**

The probability of adequacy at 30 June 2023 is 85% (2022: 85%). Professional Insurance Australia Pty Ltd's (PIA), a wholly owned subsidiary, assets and liabilities were transferred to AIL on 13 April 2022 pursuant to a Federal Court approved scheme ("Scheme Transfer") and the general insurance licence was revoked on 28 June 2022. As at 30 June 2022, PIA was considered a runoff portfolio and at this date the probability of adequacy was 99.5%. Following the Scheme Transfer, the outstanding claims liabilities transferred are recorded in AIL and are subject to a probability of adequacy of 85% as at 30 June 2023.

The probability of adequacy for the Deferred Claims Liability at 30 June 2023 is 85% (2022: 85%).

The discounted risk margin included in gross outstanding claims at 30 June 2023 is 26% (2022: 26%).

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 4. Underwriting activities (continued)

### e) Reinsurance and other recoveries

#### How we account for the numbers

Reinsurance and other recoveries on paid and outstanding claims are recognised as revenue on an accruals basis. Reinsurance and other recoveries on outstanding claims are measured at the present value of the expected future receipts, calculated on the same basis as the liability for outstanding claims. Where recoverability of an amount owing from a reinsurer or other party is in doubt, a provision for default is raised.

Included in other recoveries are amounts receivable under Commonwealth Government schemes. Recoveries on paid and outstanding claims are receivable from the Commonwealth under the Medical Indemnity Act (2002). There are four medical indemnity insurance schemes currently in place that benefit the Group:

1. High Cost Claims Scheme (HCCS):  
Under this scheme the government funds 50% of the costs of a claim that exceeds the HCCS threshold. The threshold is determined by the date of notification of the incident or claim.
2. Run-off Cover Scheme (ROCS):  
The ROCS scheme provides cover to practitioners who have ceased remunerated medical practice (retired, permanently disabled, deceased, etc). The scheme covers 100% of costs (plus a 5% claims handling fee) for claims for incidents that occurred during their medical practice. ROCS cover mirrors the last contract of insurance. The ongoing cost of ROCS is met by a ROCS support payment paid by insurers.
3. Incurred But Not Reported (IBNR) scheme:  
The IBNR scheme covers claims notified after 30 June 2002 in respect of incidents which have taken place prior to 30 June 2002 where the doctor had claims-incurred cover. The IBNR scheme covers 100% of costs (plus a 5% claims handling fee). UMP (now Avant Group Holdings Limited) is the only eligible MDO in Australia.
4. Exceptional claims scheme:  
Under this scheme the government funds 100% of claims costs that exceed the limit of a practitioner's medical indemnity insurance contract.

#### Critical accounting estimates and judgements

The Group works on the assumptions that the schemes will not be withdrawn (in whole or in part with retrospective effect).

	2023 \$ million	2022 \$ million
<b>Expected future reinsurance and other recoveries undiscounted on:</b>		
Paid claims	22.3	20.8
Outstanding claims	305.1	287.5
	327.4	308.3
Discount to present value	(46.3)	(38.7)
<b>Reinsurance contract and other recoveries asset</b>	<b>281.1</b>	<b>269.6</b>
Amounts receivable:		
Within 12 months	64.1	58.9
After more than 12 months	217.0	210.7
	<b>281.1</b>	<b>269.6</b>

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 4. Underwriting activities (continued)

### f) Claims development tables

#### Overview

The ultimate claims cost for any particular accident year is not known until all claims payments have been finalised. Most of the covers issued by the Group are long tail classes of business for which claims payments may not be finalised for many years into the future.

The claims development tables provide how the estimate of this final figure changes over time for the ten most recent years. In accordance with AASB1023 *General Insurance Contracts* there are two tables providing this both on a gross, and net of reinsurance, basis. This table, therefore, illustrates the variability and inherent uncertainty in calculating the central estimate each year.

Each table provides within it a reconciliation from the current estimate of ultimate undiscounted claims cost to gross and net outstanding claims liability as provided in note 4(d).

Claims development in the year represents the movement in undiscounted claims for the year and does not include any aspect of claims handling costs, movement in discounting or the movement in risk margin. At the end of the tables is a reconciliation to provide how the claims development reconciles to the claims cost (gross and net) provided in the consolidated statement of financial position.

Information for the consolidated claims development tables is provided on a financial year basis and is extracted from claims administration systems and actuarial models. IBNR liabilities have been included in the "2010 and prior" column.

GROSS \$'million	FY of notification of incident ended 30 June											
	2013 & Prior	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	
<b>Gross ultimate claims incurred</b>												
Original estimate	2,412.0	214.4	212.0	236.6	224.8	256.3	275.0	285.5	331.4	334.4	355.6	
1 year later	2,350.2	215.6	209.1	232.4	222.0	249.5	294.7	304.9	353.9	353.9		
2 years later	2,324.1	201.6	187.7	233.5	216.0	255.9	315.8	326.3	361.3			
3 years later	2,271.0	196.2	191.4	249.0	227.5	263.3	328.9	342.8				
4 years later	2,368.1	194.3	191.9	257.2	228.3	261.9	352.1					
5 years later	2,318.5	192.2	191.3	254.2	228.5	264.0						
6 years later	2,308.5	190.0	188.4	252.6	231.9							
7 years later	2,304.2	189.3	188.7	258.8								
8 years later	2,293.6	185.7	190.5									
9 years later	2,287.5	185.2										
10 years later	2,284.7											
												<b>Total</b>
Central estimate of ultimate undiscounted claims cost	2,284.7	185.2	190.5	258.8	231.9	264.0	352.1	342.8	361.3	353.9	355.6	5,180.8
Less: Cumulative payments to date	(2,250.5)	(181.5)	(180.2)	(230.4)	(210.7)	(235.0)	(285.5)	(262.8)	(249.9)	(202.6)	(146.1)	(4,435.2)
Central estimate of undiscounted outstanding claims liability	34.2	3.7	10.3	28.4	21.2	29.0	66.6	80.0	111.4	151.3	209.5	745.6
Discount (for all notification years combined)												(85.6)
Claims handling expenses (for all notification years combined)												46.0
Risk margin (for all notification years combined)												169.5
Member giveback liability												11.0
GST												13.2
<b>Gross discounted outstanding claims provision including claims handling expenses and risk margin</b>												<b>899.7</b>
<b>Claims development in the year (undiscounted)</b>	<b>(2.8)</b>	<b>(0.5)</b>	<b>1.8</b>	<b>6.2</b>	<b>3.4</b>	<b>2.1</b>	<b>23.2</b>	<b>16.5</b>	<b>7.4</b>	<b>19.5</b>	<b>355.6</b>	<b>432.4</b>

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 4. Underwriting activities (continued)

#### f) Claims development tables (continued)

NET \$'million	FY of notification of incident ended 30 June											Total	
	2013 & Prior	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023		
<b>Net ultimate claims incurred</b>													
Original estimate	1,892.3	170.7	175.3	196.6	189.0	221.9	245.2	257.4	291.2	290.7	324.6		
1 year later	1,854.7	169.4	173.4	190.1	186.7	213.8	252.4	274.2	303.6	300.4			
2 years later	1,826.4	161.9	159.2	187.3	182.3	218.1	270.8	280.7	300.3				
3 years later	1,790.4	160.7	161.0	197.0	190.0	225.9	274.2	288.0					
4 years later	1,882.8	159.3	161.1	200.3	191.5	222.3	285.2						
5 years later	1,885.2	157.8	159.2	200.2	188.8	223.8							
6 years later	1,878.7	155.7	156.7	198.6	189.3								
7 years later	1,875.4	155.0	156.6	198.0									
8 years later	1,871.9	153.0	157.5										
9 years later	1,866.7	152.7											
10 years later	1,865.4												
													<b>Total</b>
Central estimate of ultimate undiscounted claims cost	1,865.4	152.7	157.5	198.0	189.3	223.8	285.2	288.0	300.3	300.4	324.6	4,285.2	
Less: Cumulative payments to date	(1,849.2)	(150.8)	(151.3)	(184.8)	(176.6)	(204.2)	(240.8)	(233.0)	(221.4)	(184.2)	(144.8)	(3,741.1)	
Central estimate of undiscounted outstanding claims liability	16.2	1.9	6.2	13.2	12.7	19.6	44.4	55.0	78.9	116.2	179.8	544.1	
Discount (for all notification years combined)													(56.1)
Claims handling expenses (for all notification years combined)													41.5
Risk margin (for all notification years combined)													100.2
Recoveries receivable													(22.1)
Member giveback liability													11.0
<b>Net discounted outstanding claims provision including claims handling expenses and risk margin</b>													<b>618.6</b>
<b>Reconciliation to the consolidated balance sheet:</b>													
Gross outstanding claims liabilities													899.7
Reinsurance and other recoveries													(281.1)
<b>Net outstanding claims liabilities</b>													<b>618.6</b>
<b>Claims development in the year (undiscounted)</b>	<b>(1.3)</b>	<b>(0.3)</b>	<b>0.9</b>	<b>(0.6)</b>	<b>0.5</b>	<b>1.5</b>	<b>11.0</b>	<b>7.3</b>	<b>(3.3)</b>	<b>9.7</b>	<b>324.6</b>	<b>350.0</b>	

The following table reconciles from claims development in the year (provided in the above two claims development tables) to gross claims expense and recoveries revenue as disclosed in the consolidated statement of comprehensive income:

	Gross \$'million	Reinsurance \$'million	Net \$'million
Development tables claims movement	432.4	(82.4)	350.0
<b>Adjusted for the effect of:</b>			
Movement in discounting on claims	(36.9)	10.4	(26.5)
Movement in discounted risk margin	(11.8)	2.5	(9.3)
Discounted cost of claims handling expenses	22.9	0.1	23.0

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

Gross claims expense/(reinsurance and other recoveries revenue)	406.6	(69.4)	337.2
---	-------	--------	-------

### Note 4. Underwriting activities (continued)

#### g) Unearned income

##### How we account for the numbers

##### Unearned premiums

Gross written premium is earned in profit or loss in accordance with the pattern of incidence of risk. The unearned premium liability is that portion of gross written premium that has not yet been earned in the profit or loss, and is calculated based on the coverage period of the insurance and in accordance with the expected pattern of incidence of risk.

##### Liability adequacy test

At each balance date, the adequacy of the unearned premium liability is assessed on a net of reinsurance basis against the present value of the expected cash flows relating to potential future claims in respect of relevant insurance contracts, plus an additional risk margin to reflect the inherent uncertainty of the central estimate. This test is carried out separately for each group of contracts subject to broadly similar risks that are managed together as a single portfolio. If the unearned premium liability, less intangible assets and deferred acquisition costs is deficient, the resulting deficiency is recognised in the statement of comprehensive income of the Group.

The probability of sufficiency applied to the liability adequacy test differs from the probability of sufficiency adopted in determining the outstanding claims liabilities provision. The reason for the difference is that the former is a benchmark used to test the adequacy of the net premium liabilities whereas the latter is a measure of the sufficiency of the outstanding claims liabilities provision carried by the Company.

AASB 1023 requires the inclusion of a risk margin in insurance liabilities but does not prescribe a minimum level of margin. While there is established practice in the calculation of the probability of sufficiency of the outstanding claims liabilities provision, no such guidance exists in respect of the level of risk margin to be used in determining the adequacy of net premium liabilities. The Group has adopted a risk margin for the purpose of the liability adequacy test to produce a 75% probability of sufficiency. The 75% basis is a recognised industry benchmark in Australia, for both general insurers and health insurers and is also the basis required for reporting to APRA.

##### Unearned membership and subscription fee

Membership and subscription fee income is recognised in profit or loss as earned over the membership/ subscription period. The unearned fee is the portion of revenue that has not yet been earned in the profit or loss, and is calculated based on the period covered by the fees.

##### Critical accounting estimates and judgements

The application of the liability adequacy test in respect of the net premium liabilities identified a surplus at 30 June 2023 and 2022.

	2023 \$'million	2022 <sup>1</sup> \$'million
Unearned income at the beginning of the year	237.7	221.4
Premium, membership and subscription fees contracted during the year	452.6	430.6
Income earned during the year	(444.7)	(414.3)
<b>Unearned income liability at the end of the year</b>	<b>245.6</b>	<b>237.7</b>
Unearned membership/subscription fee income	21.7	30.4
Unearned premium liability	245.6	237.7
<b>Total unearned income liability</b>	<b>267.3</b>	<b>268.1</b>

<sup>1</sup>Prior year balance adjusted to correctly reflect the change in unearned premium during the period.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 4. Underwriting activities (continued)

#### h) Deferred expenses

##### How we account for the numbers

A portion of acquisition costs relating to unearned premium is deferred on recognition on the basis that it represents a future benefit. Deferred acquisition costs are measured at the lower of cost and recoverable amount. Deferred acquisition costs are amortised over the period related to the premium written.

	2023 \$'million	2022 \$'million
Deferred reinsurance premiums	4.7	4.0
Deferred ROCS expense	8.3	9.1
Deferred acquisition costs	10.1	9.6
<b>Deferred expenses</b>	<b>23.1</b>	<b>22.7</b>

All deferred expenses are classified as current assets.

#### i) Acquisition and other expenses

##### How we account for the numbers

Acquisition costs consist of the expenses incurred by the Group that are directly related to the acquisition of new business or renewal of existing business.

Other underwriting expenses consist of the expenses incurred by the Group that are related to the insurance business other than acquisition costs.

Other operating expenses consist of the expenses incurred by the Group that are not related to the insurance business.

	Note	2023 \$'million	2022 \$'million
Employee related costs		124.0	101.2
Director related costs		2.0	2.0
Depreciation - Right-of-use lease asset	5(f)	4.9	5.6
Depreciation - Property and equipment and intangibles		3.0	2.5
Other general and administrative expenses		46.1	38.4
<b>Total acquisition and other expenses</b>		<b>180.0</b>	<b>149.7</b>
Acquisition costs		40.2	39.3
Other underwriting expenses		44.9	41.4
Other operating expenses		94.9	69.0
<b>Total acquisition and other expenses</b>		<b>180.0</b>	<b>149.7</b>

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 5. Other operating activities

### a) Other income

#### Overview

Other income mainly relates to the earned membership subscription revenues and fees received by the Group. It also includes fees, commissions and subscriptions received by the Group's non-insurance related businesses.

#### How we account for the numbers

##### Membership subscription revenues and fees

Subscription revenues and fees are the amount charged to members, excluding taxes collected on behalf of third parties, and is recognised over the period of the membership. The portion of subscription revenues and fees received or receivable not earned in the statement of comprehensive income at the reporting date is recognised in the statement of financial position as an unearned income.

##### Other

This relates to all the revenues of the entities in the Group excluding premiums, membership subscription revenues and fees.

	2023 \$million	2022 \$million
Membership subscription revenues and fees	44.5	42.1
Income from other services	29.6	20.2
<b>Other income</b>	<b>74.1</b>	<b>62.3</b>

#### How we account for the numbers

##### Trade and other receivables

Receivables are recognised initially at fair value and subsequently measured at amortised cost less provision for impairment.

Receivables are generally due for settlement within 30 days. They are presented as current assets unless collection is not expected for more than 12 months after the reporting date.

The recoverability of receivables is reviewed on an ongoing basis. A provision for impairment is established when there is objective evidence that the Group will not be able to collect all amounts due according to the original terms of the receivable. Debts which are known to be non-recoverable are written off by reducing the carrying amount directly. Due to the short-term nature of these receivables, the carrying value is assumed to be an approximation to the fair value.

Any change in the amount of the impairment loss is recognised in profit or loss within other underwriting expenses if it relates to premium receivable, or within other operating expenses if it relates to other categories of receivables.

##### Finance lease receivables

Finance lease receivables are initially recognised at the amount equal to the net investment in the sublease. Subsequently, finance income is recognised at a constant rate on the net investment. Net investment in the sublease is the gross investment in the sublease discounted at the interest implicit in the lease. The gross investment in the sublease is the sum of the lease payments receivable by the sublessor under a finance lease. The interest rate implicit in the lease is the rate used to calculate the present value of the lease payments.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 5. Other operating activities (continued)

#### How we account for the numbers (continued)

##### Trade and other payables

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. The amounts are unsecured and, except for adjustment reinsurance premiums, are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting date. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.

##### Provisions

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and the amount has been reliably estimated. Provisions are not recognised for future operating losses.

Where there are several similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Provisions are measured at the present value of management's best estimate of the expenditure required to settle the present obligation at the statement of financial position date. The discount rate used to determine the present value reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the passage of time is recognised as interest expense.

#### b) Trade and other receivables

	Note	2023 \$'million	2022 <sup>1</sup> \$'million
Premium and subscription debtors		105.1	131.9
Finance lease receivable	5(f)	0.6	1.3
Other receivables		14.5	9.8
Loans receivable		2.8	3.0
Provision for impairment of receivables		(2.3)	(0.9)
<b>Receivables - current</b>		<b>120.7</b>	<b>145.1</b>
<b>Reconciliation of provision for impairment of receivables</b>			
Opening provision		(0.9)	(0.5)
Write-off		0.1	-
Additional provision recognised during the year		(1.5)	(0.4)
<b>Closing provision</b>		<b>(2.3)</b>	<b>(0.9)</b>

<sup>1</sup> Certain amounts have been reclassified to align with the current year's presentation.

## Notes to the consolidated financial statements

For the year ended 30 June 2023

**Note 5. Other operating activities (continued)****c) Trade and other payables**

	2023 \$'million	2022 <sup>1</sup> \$'million
Sundry creditors and accruals	57.5	43.3
Other payables	-	3.1
Reinsurance premiums payable	3.1	3.1
ROCS levy payable	7.0	7.9
Lease incentive liability	3.3	4.9
GST payable	15.9	19.1
Stamp duty payable	13.0	15.2
<b>Total trade and other payables</b>	<b>99.8</b>	<b>96.6</b>
Current payables	90.4	93.8
Non-current payables	9.4	2.8
<b>Total trade and other payables</b>	<b>99.8</b>	<b>96.6</b>

**d) Other provisions****Overview**

Other provisions relate to a restoration provision and a provision for reinsurance premium payable.

The restoration provision relates to the expected costs of returning the current leased premises to their original condition at the end of the lease term.

The provision for reinsurance premiums payable represents the adjustment premiums payable in respect of prior years' reinsurance cover. The adjustment premiums are additional reinsurance expenses payable under reinsurance contracts where recoveries under those contracts have exceeded or are expected to exceed specified items.

Movement in other provisions	Reinsurance premiums \$'million	Restoration provision \$'million	Total \$'million
Value as at 1 July 2021	0.9	1.7	2.6
Payments	(0.6)	-	(0.6)
Release of provisions	-	(0.3)	(0.3)
<b>Value as at 30 June 2022</b>	<b>0.3</b>	<b>1.4</b>	<b>1.7</b>
Additional provisions recognised	1.3	1.0	2.3
Release of provisions	(0.3)	-	(0.3)
<b>Value as at 30 June 2023</b>	<b>1.3</b>	<b>2.4</b>	<b>3.7</b>

<sup>1</sup> Certain amounts have been reclassified to align with the current year's presentation.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 5. Other operating activities (continued)

#### e) Employee-related provisions

##### Overview

Employee benefits relate to the Group's liability for long service leave and annual leave.

##### How we account for the numbers

The obligations are presented as current provisions in the statement of financial position if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur.

Current provision includes all annual leave balances and all long service leave balances where employees have completed the required period of service, since the Group does not have the unconditional right to defer settlement for any of these obligations. However, based on past experience, the Group does not expect all employees to take the full amount of accrued leave or require payment within the next 12 months. The amounts included as current, but where leave is not to be expected to be taken or paid within the next 12 months, are disclosed below.

Where employees have not completed the required period of service for long service leave, provisions are considered to be non-current and are measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method.

##### Critical accounting estimates and judgements

In calculating non-current long service leave provisions, consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of government bonds with terms to maturity that match, as closely as possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognised in profit or loss.

	Current \$'million	Non-current \$'million	Total \$'million
Value as at 1 July 2021	8.1	2.6	10.7
Additional provisions recognised	14.9	0.3	15.2
Payments	(12.9)	(0.1)	(13.0)
Reclassification	0.5	(0.5)	-
<b>Value as at 30 June 2022</b>	<b>10.6</b>	<b>2.3</b>	<b>12.9</b>
Additional provisions recognised	20.1	0.6	20.7
Payments	(18.8)	(0.2)	(19.0)
Reclassification	(0.7)	0.7	-
<b>Value as at 30 June 2023</b>	<b>11.2</b>	<b>3.4</b>	<b>14.6</b>
		<b>2023</b> \$'million	<b>2022</b> \$'million
Current leave obligation expected to be settled after 12 months		4.1	4.5

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 5. Other operating activities (continued)

### f) Leases

#### Overview

##### AASB 16 Leases

AASB 16 requires lessees to recognise most leases on the statement of financial position as lease liabilities, with a corresponding right of use assets. Lessees have the option not to recognise certain type of leases such as short-term leases and leases for which the underlying asset is of low value.

#### How we account for the numbers

##### Recognition and measurement

##### Right-of-use lease asset ('ROU')

###### Initial recognition

ROU lease assets are measured as if AASB 16 had been applied since the commencement date of the lease. The asset is initially measured as the present value of the future lease payments less any lease incentives received and discounted using the Group's incremental borrowing rate at the date of recognition.

###### Subsequent measurement

The ROU lease asset is measured at cost less accumulated depreciation and any accumulated impairment losses, and adjusted for any remeasurement of the lease liability.

Depreciation of the ROU lease asset is calculated using the straight-line method to allocate their cost over their estimated useful lives being the lesser of the remaining lease term and the life of the asset. This is presented as part of other underwriting expenses in the consolidated statement of comprehensive income.

##### Lease liabilities

###### Initial recognition

The lease liabilities are measured at the present value of the future lease payments, net of cash lease incentives, discounted using the Group's incremental borrowing rate at the date of recognition (or date when entering the lease).

###### Subsequent measurement

The lease liability is measured by:

- increasing the carrying amount to reflect interest on the lease liability;
- reducing the carrying amount to reflect the lease payments made; and
- remeasuring the carrying amounts to reflect any reassessment or lease modifications.

Lease payments exclude service fees for cleaning and other costs. Lease modifications are accounted for as a new lease. Interest expense on lease liabilities is presented as financing cost in the consolidated statement of comprehensive income.

The Group has elected not to recognise ROU lease asset and lease liabilities for leases where the lease term is less than or equal to 12 months. Payments for such leases are recognised as an expense on a straight-line basis over the lease term.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 5. Other operating activities (continued)

#### f) Leases (continued)

The following tables detail the carrying amount of right-of-use lease assets, lease liabilities and finance lease receivable and the movements during the year.

##### Right-of-use lease assets:

The ROU lease asset recognised by the Group are buildings and technology in nature.

	2023 \$'million	2022 \$'million
Opening balance	29.4	24.2
Net addition during the year	2.2	10.8
Depreciation expense	(4.9)	(5.6)
<b>Closing balance – non-current</b>	<b>26.7</b>	<b>29.4</b>

##### Finance lease receivable:

The asset subleased by the Group are buildings in nature.

	2023 \$'million	2022 \$'million
Opening balance	1.3	2.0
Sublease receipts	(0.7)	(0.7)
<b>Closing balance</b>	<b>0.6</b>	<b>1.3</b>
Current receivable	0.6	0.7
Non-current receivable	-	0.6
<b>Finance lease receivable</b>	<b>0.6</b>	<b>1.3</b>

##### Lease liabilities:

	2023 \$'million	2022 \$'million
Opening balance	33.3	29.4
Net addition during the year	2.2	10.3
Interest expense	1.2	0.7
Payments made	(7.2)	(6.4)
<b>Closing balance</b>	<b>29.5</b>	<b>33.3</b>
Current payables	5.1	5.5
Non-current payables	24.4	27.8
<b>Lease liabilities</b>	<b>29.5</b>	<b>33.3</b>

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 6. Financial risk management

### Overview

A financial asset is any asset which is cash, an equity instrument of another entity, or a contractual right to receive cash or another financial asset from another entity.

A financial liability is a contractual obligation to deliver cash or another financial asset to another entity.

AASB 7 *Financial Instruments: Disclosures* requires disclosure of the risks associated with financial instruments (assets and liabilities), numerical information around the quantum of the exposures to each risk and the management approach to mitigating those risks. AASB 1023 *General Insurance Contracts* specifically requires assets and liabilities arising from insurance contracts to be included within that disclosure.

The Group's activities expose it to a variety of financial risks: These include market risk (including interest rate risk, equity price risk, currency risk and other price risk), credit risk and liquidity risk. The Group's overall risk management program focuses on the unpredictability of financial markets and manages these risks within the agreed risk appetite.

The risks are controlled by ensuring that all activities are transacted in accordance with approved mandates, strategies and limits.

J. P. Morgan Investor Services Australia is the Group's appointed custodian for the AIL and AGHL investment portfolios and Frontier Advisors Pty Ltd is the Group's investment advisor. The Group invests in managed funds managed by external managers, direct securities managed by AIL and direct securities managed by external managers in accordance with terms outlined in Investment Management Agreements (IMA). Full responsibility and accountability for the Group's financial assets is maintained by the Group through the Boards of the relevant Group entities, management and the Group Investment Committee.

The investment strategies for the legal entities in the Group consider the investment risk tolerances and long-term risk-return requirements for those legal entities.

The Group's financial and insurance-related assets and liabilities at the statement of financial position date are as follows:

	2023 \$ million	2022 <sup>1</sup> \$ million
<b>Financial assets</b>		
Cash at bank	142.5	99.6
Trade and other receivables	120.7	145.1
Investments (net of derivative liabilities)	2,058.9	2,015.1
Reinsurance and other recoveries	281.1	269.6
	<b>2,603.2</b>	<b>2,529.4</b>
<b>Financial liabilities</b>		
Trade and other payables	99.8	96.6
Insurance contract liabilities	899.7	892.6
Lease liabilities	29.5	33.3
	<b>1,029.0</b>	<b>1,022.5</b>

<sup>1</sup> Certain amounts have been reclassified to align with the current year's presentation.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 6. Financial risk management (continued)

### a) Credit risk

#### Overview

Credit risk is the risk of not recovering money owed to Avant by third parties as well as the loss of value of assets due to deterioration in credit quality and is managed on a group basis.

Credit risk arises from deposits with banks and financial institutions, investments in interest rate securities, credit derivatives, reinsurance recovery exposures as well as credit exposures to customers, including outstanding premium receivables and derivative counterparties.

The following policies and procedures are in place to mitigate the Group's exposure to credit risk:

- a) The Avant Group Risk Management Strategy and the Risk Appetite Statement define what constitutes credit risk for the Group. The Risk Appetite Statement also sets certain tolerances for credit risk from reinsurers. Credit risk in respect of trade and other receivables is actively monitored. Strict controls are maintained over counterparty exposures. Business is transacted with counterparties that have a strong credit rating and concentration of risk is avoided by adherence to counterparty limits that are set each year by management and the Board of Directors, and which are reviewed by management on a regular basis.
- b) The Group Investment Policy includes credit and concentration limits for portfolios holding direct assets and ranges covering the asset classes allocated to including those exposed to credit risk. Granular credit limits are included in Investment Management Agreements in the case of externally managed portfolios. For investments in managed funds, due diligence is carried out in relation to the investment strategies adopted by the funds as documented in the funds' disclosure documents.
- c) The carrying amounts of financial assets and financial liabilities included in the consolidated statement of financial position represent the Group's maximum exposure to credit risk in relation to these assets and liabilities. Credit risk is addressed by limiting the aggregate exposure to any single counterparty by prescribing the credit quality of the counterparties, and by prescribing credit policies to directly manage credit exposures. With respect to reinsurance, a minimum of two participants on any layer of reinsurance is required, with a minimum of five reinsurers on the program. No reinsurer will be allocated a share equal to more than 50% of any original insurance policy claim exposure. The current year's reinsurance program must have a weighted average Standard and Poor's credit rating of A+.

A provision for impairment of receivables was raised on debts that are more than 90 days past due, except for the exposures under scheduled payment plan and identified by Management as fully recoverable. The Provision for impairment of receivables is disclosed in Note 5(b).

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 6. Financial risk management (continued)

### a) Credit risk (continued)

The following tables provide information regarding the aggregate credit risk exposure of the Group at the statement of financial position date in respect of the major classes of financial assets. The analysis classifies the assets according to Standard & Poor's counterparty credit ratings. AAA is the highest possible rating. The 'not rated' investment category includes unlisted managed funds where credit ratings are not applicable. These have been included in the table for completeness.

As at 30 June 2023	Credit rating					Total \$'million
	AAA \$'million	AA \$'million	A \$'million	BBB \$'million	Not rated \$'million	
Cash at bank	-	142.5	-	-	-	142.5
Receivables	-	-	-	-	120.7	120.7
Investments (net of derivative liabilities)	151.9	104.6	93.6	111.9	1,596.9	2,058.9
Reinsurance and other recoveries	270.2	4.9	6.0	-	-	281.1
<b>Total financial assets net of derivative liabilities</b>	<b>422.1</b>	<b>252.0</b>	<b>99.6</b>	<b>111.9</b>	<b>1,717.6</b>	<b>2,603.2</b>

As at 30 June 2022 <sup>1</sup>	Credit rating					Total \$'million
	AAA \$'million	AA \$'million	A \$'million	BBB \$'million	Not rated \$'million	
Cash at bank	-	94.4	5.2	-	-	99.6
Receivables	-	-	-	-	145.1	145.1
Investments (net of derivative liabilities)	47.0	60.2	125.1	240.4	1,542.4	2,015.1
Reinsurance and other recoveries	261.2	4.5	3.3	-	0.6	269.6
<b>Total financial assets net of derivative liabilities</b>	<b>308.2</b>	<b>159.1</b>	<b>133.6</b>	<b>240.4</b>	<b>1,688.1</b>	<b>2,529.4</b>

### b) Market risk

#### Overview

Market risk is the risk of diminution in value of the Group's investment portfolio arising from adverse movements in the levels and volatility of interest rates, equity prices, currency and other price risk.

#### (i) Interest rate risk

#### Overview

Financial instruments with floating interest rate expose the Group to cash flow interest rate risk, whereas fixed interest rate instruments expose the Group to fair value interest rate risk.

A genuinely long-term investment perspective allows Avant to match insurance liability movements over the longer term with superior risk adjusted returns under a capital management framework. Interest rate risk is actively managed as part of the investment portfolios to achieve a balance between the return objective of the portfolios and the Group's appetite for interest rate risk.

Net outstanding claims liabilities are non-interest-bearing financial liabilities. The net central estimate of outstanding claims liabilities is discounted to its present value by reference to risk-free interest rates. This therefore exposes the Group to underwriting result volatility as a result of interest rate movements. Refer to Note 4 (c) for the sensitivity analysis.

Reinsurance and other recoveries and insurance contract and insurance contract liabilities are subject to discounting and the sensitivity analysis is disclosed in Note 4 (c).

<sup>1</sup>Certain amounts have been reclassified to align with the current year's presentation.

## Notes to the consolidated financial statements

For the year ended 30 June 2023

**Note 6. Financial risk management (continued)****b) Market risk (continued)****(i) Interest rate risk (continued)**

The Group's sensitivity to movements in interest rates in relation to the value of financial assets on the Group's statement of comprehensive income and statement of financial position is provided in the table below:

	Movement in variable	Financial impact <sup>1</sup>	
		2023 \$'million	2022 \$'million
Managed funds	100 bp +	(1.6)	(1.2)
	100 bp -	1.6	1.2
Directly held instruments	100 bp +	(10.5)	(9.9)
	100 bp -	10.5	9.9

**(ii) Equity price risk****Overview**

Equity price risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices, whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded on the market.

The Group is exposed to equity price risk due to investments in listed and unlisted equity financial instruments and investments in managed funds investing in listed and unlisted equity financial instruments.

To manage equity price risk, the Group diversifies its underlying equity exposure by investing in multiple managed funds and in the case of directly held equity instruments, ensuring that equity portfolios are appropriately diversified.

The potential impact of movements in the price of equity financial instruments on the Group's statement of comprehensive income and statement of financial position is provided in the sensitivity analysis below:

	Movement in variable	Financial impact <sup>1</sup>	
		2023 \$'million	2022 \$'million
Managed funds	20% +	59.6	70.0
	20% -	(59.6)	(70.0)
Directly held instruments	20% +	26.6	28.5
	20% -	(26.6)	(28.5)

<sup>1</sup>Net of taxation at the *prima facie* tax rate of 30%.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 6. Financial risk management (continued)

### b) Market risk (continued)

#### (iii) Other price risk

##### Overview

Other price risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices not directly related to broad changes in equity prices, interest rates, credit spreads, interest rates and exchange rates, whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded on the market.

The Group is exposed to other price risk due to investments in managed funds investing in listed and unlisted financial instruments. Managed funds exposed to other price risk include those employing absolute return strategies.

To manage other price risk the Group invests in multiple managed funds and, in the case of directly held instruments, invests in multiple instruments.

The potential impact of movements in the price of financial instruments exposed to other price risk on the Group's statement of comprehensive income and statement of financial position is provided in the sensitivity analysis below:

	Movement in variable	Financial impact <sup>1</sup>	
		2023 \$'million	2022 \$'million
Managed funds	10% +	25.2	36.4
	10% -	(25.2)	(36.4)

#### (iv) Currency risk

##### Overview

Currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in exchange rates, whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded on the market.

The Group is exposed to currency risk due to investments in financial instruments exposed to exchange rate movements and investments in managed funds investing in financial instruments exposed to exchange rate.

To manage currency risk, entities in the Group have targets and limits in relation to currency exposure.

The potential impact of movements in exchange rates on the Group's statement of comprehensive income and statement of financial position is provided in the sensitivity analysis below:

	Movement in variable	Financial impact <sup>1</sup>	
		2023 \$'million	2022 \$'million
Managed funds	20% +	21.4	19.2
	20% -	(21.4)	(19.2)
Directly held instruments	20% +	20.9	21.4
	20% -	(20.9)	(21.4)

<sup>1</sup> Net of taxation at the *prima facie* tax rate of 30%.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 6. Financial risk management (continued)

### c) Liquidity risk

#### Overview

Liquidity risk is the risk that the Group will be unable to meet its financial obligations as they fall due, or only being able to achieve the required level of liquidity at excessive cost. In the Group, this risk arises due to the nature of insurance activities where the timing and amount of cash outflows are uncertain.

The following policies and procedures are in place to mitigate the Group's exposure to liquidity risk:

- The Group manages liquidity risk by maintaining sufficient cash and liquid investments.
- Liquidity risk is addressed by imposing restrictions on the quality of assets which can be held and by having in place plans for managing liquidity under different scenarios to ensure the Group can operate for a minimum time under adverse conditions.

The tables below summarise the maturity profile of:

- financial liabilities of the Company based on the remaining undiscounted contractual obligations.
- outstanding claims liabilities on an undiscounted basis.
- the discounted values reported in the statement of financial position.

As at 30 June 2023	0-3 months \$'million	3-6 months \$'million	6-12 months \$'million	1-2 years \$'million	Over 2 years \$'million	Total	
						Undiscounted \$'million	Discounted \$'million
Trade and other payables	81.9	0.5	8.1	1.1	8.2	99.8	99.8
Derivative liabilities	0.6	-	-	-	-	0.6	0.6
Insurance contract liabilities undiscounted	80.0	75.4	123.9	205.7	522.6	1,007.6	899.7
Lease liabilities undiscounted	1.8	1.8	3.5	5.5	20.1	32.7	29.5
	<b>164.3</b>	<b>77.7</b>	<b>135.5</b>	<b>212.3</b>	<b>550.9</b>	<b>1,140.7</b>	<b>1,029.6</b>

As at 30 June 2022 <sup>1</sup>	0-3 months \$'million	3-6 months \$'million	6-12 months \$'million	1-2 years \$'million	Over 2 years \$'million	Total	
						Undiscounted \$'million	Discounted \$'million
Trade and other payables	89.2	0.5	4.1	2.1	0.7	96.6	96.6
Derivative liabilities	2.9	-	-	-	-	2.9	2.9
Insurance contract liabilities undiscounted	84.1	65.2	99.8	200.8	532.3	982.2	892.6
Lease liabilities undiscounted	1.6	1.7	3.2	6.7	24.3	37.5	33.3
	<b>177.8</b>	<b>67.4</b>	<b>107.1</b>	<b>209.6</b>	<b>557.3</b>	<b>1,119.2</b>	<b>1,025.4</b>

At the request of the Group, Westpac Banking Corporation Limited has undertaken to pay on demand amounts up to \$8.2m (2022: \$8.2 m) in respect of lease payments payable. This bank guarantee is secured by a fixed charge over the Group's cash deposits.

<sup>1</sup>Certain amounts have been reclassified to align with the current year's presentation.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 7. Capital management

### Overview

The Group's objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can continue to provide benefits for its stakeholders, including its members, and to meet its obligations to policyholders.

The Group has a comprehensive Internal Capital Adequacy Assessment Process (ICAAP) which documents the various practices governing the management of the Group's capital. The policy articulates the Group's tolerance to capital management risk and how these practices manage the Group's risk tolerance framework.

The Group allocates its consolidated net assets to several purposes including:

- a) Capital in its APRA regulated insurance subsidiary (AIL) held to meet APRA regulatory and target surplus capital requirements within the entity. The amount of capital at 30 June 2023 and its basis for determination is summarised in section (a) below.
- b) Capital in DHF held to meet APRA regulatory and target surplus capital requirements within the entity. The amount of capital at 30 June 2023 and its basis for determination is summarised in section (b) below.
- c) Intercompany undertakings: As part of a group-wide initiative to centrally manage capital, capital is held within AGHL which supports capital guarantees provided to AIL and DHF. This is managed through Deeds of Undertaking from AGHL to AIL of \$215,000,000 and from AGHL to DHF of \$17,000,000, and is part of a capital buffer layer in the event that the entities' regulatory capital adequacy multiple falls below a minimum ratio of 1.5.
- d) Capital notionally held to support the Retirement Reward Plan (RRP) noting that the directors maintain sole discretion to declare RRP dividends. The Company does not carry a present obligation to provide the amount at balance date other than any declared dividend amount in the period that has not yet been paid at balance date.
- e) Other capital reserves held to support Group business initiatives to enhance and grow its membership offerings and services to policyholders including the RRP.

### a) APRA Capital Adequacy Multiple

#### Overview

The Group's insurance subsidiary, AIL, is regulated by APRA. The capital base, prudential capital requirement and capital adequacy multiple of AIL are provided in the following table.

APRA Prudential Standard GPS 110 Capital Adequacy for General Insurers requires that the Company maintains a capital base in excess of its prudential capital requirement as defined under the Prudential Standard.

APRA Prudential Standard GPS 340 Insurance Liability Valuation establishes a set of principles for the consistent measurement and reporting of the insurance liabilities of all general insurers. GPS 340 requires that the Company establish a basis that would be expected to secure the insurance liabilities of the insurer at a 75% level of sufficiency.

A Board-approved Internal Capital Adequacy Assessment Process (ICAAP) has been in place during the year to ensure AIL's capital is managed adequately, in line with its risk appetite, and target capital requirements.

AIL manages its capital to achieve the following objectives:

- continuation as a going concern;
- ongoing compliance with APRA prudential framework;
- remaining within the Company's risk appetite boundaries as set out in the RAS (Risk Appetite Statement) including the capital boundary;
- compliance with the financial requirements of the Australian Financial Services Licence issued by the Australian Securities and Investments Commission; and
- compliance with the Group's capital management framework and strategy.

Management monitors the capital positions regularly and reports the capital position to the Board.

## Notes to the consolidated financial statements

For the year ended 30 June 2023

**Note 7. Capital management (continued)****a) APRA Capital Adequacy Multiple (continued)**

The following tables provide the capital adequacy of AIL calculated in accordance with APRA prudential framework.

**(i) AIL**

	2023 \$'million	2022 \$'million
Eligible Tier 1 Capital as defined by APRA		
Contributed equity	223.7	223.7
Reserves	66.6	66.6
Retained profits <sup>1</sup>	154.1	122.0
Insurance liability surplus	36.7	24.4
Total equity	481.1	436.7
Less: APRA deductions	(34.9)	(41.9)
<b>APRA capital base</b>	<b>446.2</b>	<b>394.8</b>
Asset risk charge	93.1	112.8
Insurance risk charge	117.9	115.5
Insurance concentration risk charge	27.0	33.0
Operational risk charge	19.1	19.4
Aggregation benefit	(50.7)	(57.6)
<b>APRA prudential capital requirement</b>	<b>206.4</b>	<b>223.1</b>
<b>APRA capital adequacy multiple</b>	<b>2.16</b>	<b>1.77</b>

**Insurance liability surplus**

APRA Prudential Standard GPS 340 *Insurance Liability Valuation* requires that the Company establish reserves on a basis that would be expected to secure the insurance liabilities of the insurer at a 75% level of sufficiency.

The value of the insurance liabilities for outstanding claims required by GPS 340 differs from accounting purposes for the following reasons:

- i. GPS 340 requires a prudential margin with a probability of sufficiency of 75%, the level adopted by the Company for accounting purposes is 85% (2022: 85%) for AIL
- ii. GPS 340 requires an assessment of premium liability (unearned premium less deferred acquisition costs, deferred reinsurance expense and ROCS levy is used for accounting purposes). The surplus between the premium liabilities per APRA requirements and premium liabilities per AASB 1023 *Premium Liabilities* is included in Tier 1 capital.

<sup>1</sup> Retained profits are measured in accordance with APRA Prudential Standards.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 7. Capital management (continued)

### b) APRA capital adequacy and solvency requirements

#### (ii) DHF

##### Overview

The Group's private health insurance subsidiary, DHF, has been regulated by APRA since 1 July 2015. The Private Health Insurance Administration Council (PHIAC) was the regulator up until 30 June 2015. Solvency and capital adequacy standards are established under the *Private Health Insurance Act 2007* (the Act), and are an integral component of the prudential reporting and management regime for private health insurers. DHF is subject minimum capital requirement prescribed by the APRA prudential standards for private health insurers. DHF maintains a target level of surplus capital in excess of that minimum. This is to ensure that, under a range of adverse circumstances, DHF would be expected to be in a position to meet its existing and future obligations to members and other creditors, in the context of a viable ongoing operation. APRA introduced changes to the private health insurance capital framework to be more aligned to those applicable to general insurers. APRA released the final standards on 27 September 2022 for implementation on 1 July 2023. An impact assessment for the adoption of the final standards is in progress.

The following table provides the capital adequacy calculated in accordance with the APRA prudential standards:

	2023 \$'million	2022 \$'million
Total assets	126.9	118.6
Total liabilities	83.0	84.9
<b>Net assets</b>	<b>43.9</b>	<b>33.7</b>
<b>APRA capital adequacy reserve</b>	<b>18.5</b>	<b>15.3</b>
<b>APRA capital adequacy multiple</b>	<b>2.37</b>	<b>2.20</b>

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 8. Income tax

### Overview

The income tax expense or revenue for the period is the tax payable/receivable on the current period's taxable income based on the applicable income tax rate adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

The Company and its controlled entities AGHL and MDAV are limited by guarantee and operate for the mutual benefit of their members. These entities have been treated as mutuals such that they are not liable for income tax on membership income nor are the outgoings related to that income allowable as income tax deductions. These entities are, however, liable to income tax on investment income, capital profits, and income from insurance-related activities.

### *Tax consolidation legislation*

The Company and its wholly-owned Australian controlled entities have implemented the tax consolidation legislation. As a consequence, these entities are taxed as a single entity and the deferred tax assets and liabilities of these entities are set off in the consolidated financial statements.

The Company (head entity of the tax consolidation group) and the controlled entities in the tax consolidated group (TCG) account for their own current and deferred tax amounts. These tax amounts are measured as if each entity in the tax consolidated group continues to be a stand-alone taxpayer in its own right.

In addition to its own current and deferred tax amounts, the Company also recognises the current tax liabilities (or assets) and the deferred tax assets arising from losses and unused tax credits assumed from controlled entities in the tax consolidated group.

Assets and liabilities arising under tax funding agreements with the tax consolidated entities are recognised as amounts receivable from or payable to other entities in the Group.

Any difference between the amounts assumed and amounts receivable or payable under the tax funding agreement are recognised as a contribution to (or distribution from) wholly-owned tax consolidated entities.

### How we account for the numbers

Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

### Deferred income tax

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit nor loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Deferred tax liabilities are not recognised for temporary differences between the carrying amount and tax bases of the investments in controlled entities where the parent entity is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 8. Income tax (continued)

	2023 \$'million	2022 \$'million
<b>a) Income tax (benefit)/expense</b>		
Current tax expense	23.7	33.4
Deferred tax expense/(benefit)	12.4	(60.8)
Over provision in prior years	(3.1)	(1.4)
<b>Income tax expense/(benefit)</b>	<b>33.0</b>	<b>(28.8)</b>
<b>b) Numerical reconciliation of income tax expense</b>		
Profit/(loss) from continuing operations before income tax	129.7	(76.9)
Tax/(benefit) at Australian tax rate of 30% (2022: 30%)	38.9	(23.0)
Net mutual income - non assessable	(3.9)	(4.4)
Other permanent differences	4.1	3.1
Effect of franking credits and foreign income tax offsets	(3.0)	(3.1)
Over provision in prior years	(3.1)	(1.4)
<b>Income tax expense/(benefit)</b>	<b>33.0</b>	<b>(28.8)</b>
<b>c) Deferred tax<sup>1</sup></b>		
The balance comprises temporary differences attributable to:		
<b>Amounts recognised in the profit or loss relating to:</b>		
<b>Deferred tax assets<sup>2</sup>:</b>		
Accruals and provisions	40.1	33.4
Financial assets	-	9.1
Tax losses recognised	-	5.3
Other	-	3.5
<b>Total deferred tax assets before application of set-off</b>	<b>40.1</b>	<b>51.3</b>
Set-off against deferred tax liabilities	(1.5)	(0.3)
<b>Total deferred tax assets after set-off</b>	<b>38.6</b>	<b>51.0</b>
<b>Deferred tax liabilities:</b>		
Financial assets	1.3	-
Investment in associates	0.2	0.2
Interest receivable	-	0.1
<b>Total deferred tax liabilities before application of set-off</b>	<b>1.5</b>	<b>0.3</b>
Set-off against deferred tax assets	(1.5)	(0.3)
<b>Total deferred tax liabilities after set-off</b>	<b>-</b>	<b>-</b>
<b>Net deferred tax (liability)/asset movements:</b>		
Opening balance at the beginning of the year	51.0	(8.8)
Prior year over provision	-	(1.0)
(Released)/charged to the income statement	(12.4)	60.8
<b>Closing balance at the end of the year</b>	<b>38.6</b>	<b>51.0</b>

<sup>1</sup> Deferred tax assets are classified as non-current.

<sup>2</sup> Prior year comparatives have been represented to align with the current year disclosures. The representation had no impact on the Group's other comprehensive income or statement of financial position.

## Notes to the consolidated financial statements

For the year ended 30 June 2023

**Note 8. Income tax (continued)****d) Current tax liabilities**

	<b>2023</b>	<b>2022</b>
	<b>\$'million</b>	<b>\$'million</b>
Opening balance at the beginning of the year	26.3	30.7
Payment of prior year tax liabilities	(34.3)	(28.2)
Payment of current year tax liabilities	(10.1)	(4.1)
Over provision	(0.1)	(2.5)
Effect of franking credits and foreign income tax credits	(3.0)	(3.0)
Current year provision	23.7	33.4
<b>Closing balance at the end of the year</b>	<b>2.5</b>	<b>26.3</b>

**e) Franking credits**

Franking credits available for the subsequent financial years based on a tax rate of 30% (2022: 30%)	432.9	386.7
--	-------	-------

**f) Tax consolidation legislation**

The Company and its wholly-owned Australian controlled entities implemented the tax consolidation legislation from 1 July 2007.

On adoption of the tax consolidation legislation, the entities in the tax consolidated group (TCG) have entered into a tax sharing agreement which, in the opinion of the Directors, limits the joint and several liability of the wholly-owned entities in the case of a default by the Company.

The entities have also entered into a tax sharing and tax funding agreement under which the wholly-owned entities fully compensate the Company for any current tax payable assumed, and are compensated by the Company for any current tax receivable and deferred tax assets relating to unused tax losses or unused tax credits that are transferred to the Company under the tax consolidation legislation. The funding amounts are determined by reference to the amounts recognised in the wholly-owned entities' financial statements.

The amount receivable/payable under the tax funding agreement is due upon receipt of the funding advice from the Company, which is issued as soon as practicable after the end of each financial year. The Company may also require payment of interim funding amounts to assist with its obligations to pay tax instalments.

Non-wholly owned controlled entities are not members of the TCG and are hence taxed separately. As a result, income tax consequences may arise between these entities and the TCG that are not eliminated in these financial statements.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 9. Property and equipment

### Overview

The Group uses property and equipment to assist in carrying out its primary operating activities. Assets are classified by the Group as office furniture and fittings, office computer equipment and leasehold improvements.

### How we account for the numbers

Property and equipment are recognised at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of items. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably.

Depreciation on the assets is calculated using the straight-line method to write off the net cost of each item over its expected useful life to the Group, or for leasehold improvements over the unexpired period of the lease, if this is shorter. Estimates of remaining useful lives are made on a regular basis for all assets, with annual reassessments for major items. An asset's carrying amount is written down to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

When items are sold, the proceeds of the sale are compared with the carrying amount to determine if there is a gain or loss, which is then included in the statement of comprehensive income.

### Critical accounting estimates and judgements

To calculate depreciation, the Group uses an estimate of how long the assets will be held for. The expected useful lives of the assets are as follows:

Leasehold improvements	6–10 years
Office furniture and fittings	10–13 years
Office and computer equipment	3–4 years

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 9. Property and equipment (continued)

2023	Office furniture and fittings \$'million	Office and computer equipment \$'million	Leasehold improvements \$'million	Total \$'million
<b>Cost</b>				
At the beginning of the year	0.5	6.9	17.9	25.3
Additions	0.2	0.6	0.4	1.2
Written off in the year	-	(0.2)	(0.6)	(0.8)
<b>At the end of the year</b>	<b>0.7</b>	<b>7.3</b>	<b>17.7</b>	<b>25.7</b>
<b>Accumulated depreciation</b>				
At the beginning of the year	0.4	5.5	11.5	17.4
Depreciation expense for the year	0.1	0.7	1.4	2.2
<b>At the end of the year</b>	<b>0.5</b>	<b>6.2</b>	<b>12.9</b>	<b>19.6</b>
<b>Net carrying value at 30 June 2023</b>	<b>0.2</b>	<b>1.1</b>	<b>4.8</b>	<b>6.1</b>
<b>2022</b>				
<b>Cost</b>				
At the beginning of the year	0.5	5.8	20.8	27.1
Additions	-	1.1	0.2	1.3
Written off in the year	-	-	(3.1)	(3.1)
<b>At the end of the year</b>	<b>0.5</b>	<b>6.9</b>	<b>17.9</b>	<b>25.3</b>
<b>Depreciation</b>				
At the beginning of the year	0.4	4.7	11.1	16.2
Depreciation expense for the year	-	0.8	0.4	1.2
<b>At the end of the year</b>	<b>0.4</b>	<b>5.5</b>	<b>11.5</b>	<b>17.4</b>
<b>Net carrying value at 30 June 2022</b>	<b>0.1</b>	<b>1.4</b>	<b>6.4</b>	<b>7.9</b>

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 10. Intangible assets

### Overview

Intangible assets are identifiable non-physical assets which have expected future economic benefits that will flow to the entity and can be reliably measured. The fact that it is identifiable distinguishes it from goodwill.

The Group holds three types of intangible assets which are:

#### Customer relationships

Customer relationships comprise the capitalisation of future profits relating to insurance contracts acquired, and the expected renewal of those contracts. It also includes the value of the distribution networks and agency relationships. Customer relationships are amortised over the remaining period of estimated useful life.

#### Software

Software represents both the acquired and internally developed software which is not integral or closely related to an item of hardware.

#### Goodwill

This represents the future economic benefits arising from assets acquired in the acquisition of Darjack Pty Limited, JRB Technologies Pty Ltd, KA JV Pty Ltd and HMPM Pty Ltd (Hoxton).

### How we account for the numbers

#### Customer relationships

Customer relationships are measured at their fair value at the date of acquisition less accumulated amortisation. They are amortised based on the timing of projected cash flows that will emerge from the block of in-force business and business expected to be renewed from this block of business, over its estimated useful life of 10 years on a straight-line basis.

#### Software

Software is recognised at cost less accumulated amortisation and impairment. The cost includes expenditure that is directly attributable to the acquisition or development of the asset. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably.

Amortisation of the assets is calculated using the straight-line method to write off the net cost of each item over its expected useful life to the Group. An asset's carrying amount is written down to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

#### Goodwill

Goodwill is measured as the excess of the cost of acquisition incurred by the Group over the fair value of the identifiable net assets. Goodwill is tested for impairment annually or more frequently if events or changes in circumstances indicate that it might be impaired and is carried at cost less accumulated impairment losses. The purchase price allocation of the goodwill to other intangible assets has been determined provisionally. Any changes to the amounts recognised will be accounted for and disclosed in the following year's financial statements.

### Critical accounting estimates and judgements

Intangible assets held by the Group, except for goodwill, are deemed to have a finite useful life.

Management has reviewed the finite useful life at year end and deemed that there has been no change in the expected pattern of consumption of future economic benefits. In addition, management expects that the consumption will continue to occur in an even straight-line pattern.

The expected useful lives of intangible assets are as follows:

Customer relationships	10 years
Software	0-4 years

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 10. Intangible assets (continued)

	Customer relationship \$'million	Software \$'million	Goodwill \$'million	Total \$'million
<b>Cost</b>				
As at 30 June 2021	5.4	8.3	6.5	20.2
Additions	-	0.7	-	0.7
Written off/impaired in the year	(0.1)	-	-	(0.1)
As at 30 June 2022	5.3	9.0	6.5	20.8
Additions	-	1.2	10.1	11.3
Written off/impaired in the year	(0.2)	-	(3.9)	(4.1)
<b>As at 30 June 2023</b>	<b>5.1</b>	<b>10.2</b>	<b>12.7</b>	<b>28.0</b>
<b>Accumulated amortisation</b>				
As at 30 June 2021	4.6	6.3	-	10.9
Amortisation expense for year ended 30 June 2022 (a)	0.5	0.8	-	1.3
As at 30 June 2022	5.1	7.1	-	12.2
Amortisation expense for year ended 30 June 2023 (a)	-	0.8	-	0.8
<b>As at 30 June 2023</b>	<b>5.1</b>	<b>7.9</b>	<b>-</b>	<b>13.0</b>
<b>Net carrying value at:</b>				
30 June 2022	0.2	1.9	6.5	8.6
<b>30 June 2023</b>	<b>-</b>	<b>2.3</b>	<b>12.7</b>	<b>15.0</b>
<b>Remaining years useful life at:</b>				
30 June 2022		3 to 5 years		
<b>30 June 2023</b>		<b>0 to 4 years</b>		

#### a) Reconciliation of amortisation expense to the Statement of comprehensive income

	30 June 2023	30 June 2022
Total amortisation expense for the year	0.8	1.3
Less: Amortisation expense - Software which is included in other underwriting expenses	(0.8)	(0.8)
<b>Amortisation of intangible assets presented in the Statement of comprehensive income</b>	<b>-</b>	<b>0.5</b>

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 11. Equity

### Overview

AMGL is a mutual company, whose ownership base is made up of its members. As such, the company does not have share capital, but rather accumulated surpluses to which the members have a joint entitlement to.

The Board of AMGL has determined that the best method of returning surpluses to members is through the discretionary payment of dividends. The Company is the first medical defence organisation in Australia to pay fully franked dividends to members.

### How we account for the numbers

#### Business combination reserve

The consolidated reserves relate to the portfolio transfer of Professional Indemnity Insurance Company Australia Pty Limited's (PIICA) assets to AIL on 30 September 2007 when PIICA ceased to offer insurance policies. PIICA was the insurer of MDAV prior to the merger of AGHL and MDAV in 2007.

#### Accumulated surpluses

The Group has separated its accumulated surpluses between those derived from mutual tax-exempt activities and those derived from mutual, but taxable activities including the activities of AIL and PIA. The Group has franking credits that would only be available for distribution from accumulated surpluses derived from mutual but taxable activities.

### a) Reserves

	2023 \$'million	2022 \$'million
<b>Business combination reserve</b>		
At the beginning and at the end of the year	54.6	54.6

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 11. Equity (continued)

#### b) Accumulated surpluses to members of Avant Mutual Group Limited

	2023 \$'million	2022 \$'million
<b>At the beginning of the year</b>		
Mutual - Tax exempt	282.2	268.6
Mutual - Taxable	984.9	1,053.9
Balance as at 1 July	1,267.1	1,322.5
<b>Total comprehensive income/(loss) for the year</b>		
Mutual - Tax exempt	13.0	14.2
Mutual - Taxable	87.3	(58.5)
	100.3	(44.3)
<b>Transactions with minority shareholders</b>		
Mutual - Tax exempt	-	-
Mutual - Taxable	(10.3)	-
	(10.3)	-
<b>Dividends paid in the year</b>		
Mutual - Tax exempt	(0.8)	(0.6)
Mutual - Taxable	(13.6)	(10.5)
	(14.4)	(11.1)
<b>At the end of the year</b>		
Mutual - Tax exempt	294.4	282.2
Mutual - Taxable	1,048.3	984.9
<b>Balance as at 30 June</b>	<b>1,342.7</b>	<b>1,267.1</b>

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 12. Remuneration of key management personnel

### Overview

AASB 124 *Related party disclosures* requires disclosure of the compensation of directors (executive and non-executive) and those persons having authority and responsibility for planning, directing and controlling the activities of the Group (collectively defined as key management personnel (KMP)).

ASIC Corporations (rounding in Financial/Directors' Reports) Instrument 2016/191 requires the amounts to be disclosed rounded to the nearest \$'000.

### How we account for the numbers

KMP remuneration excludes insurance premiums paid in respect of Directors' and officers' liability insurance contracts as the contracts do not specify premiums paid in respect of individual Directors and officers. Information relating to the insurance contract is set out in the Directors' report.

Remuneration of KMP is included in the disclosure for the period of employment during the financial year for which they are a KMP.

### Critical accounting estimates and judgements

KMP includes the Company Directors (as detailed in the Directors' Report on page 1), the Managing Director (MD) and those executives that report solely and directly to the aforementioned person.

Details of the remuneration of the KMP of the Group are provided below:

	2023 \$'000	2022 \$'000
<b>Short-term employee benefits</b>		
Cash salary, short-term bonuses, and fees	7,792	9,073
<b>Other long-term employee benefits</b>	1,776	1,063
<b>Post-employment benefits</b>		
Superannuation	562	472
<b>Termination benefits</b>	993	180
<b>Total remuneration</b>	<b>11,123</b>	<b>10,788</b>

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 13. Remuneration of auditors

#### Overview

Details of audit remuneration are required under AASB 1054 "Australian Additional Disclosures". These are required to be disclosed rounded to the nearest \$'000 as per ASIC Corporations (rounding in Financial/ Directors' Reports) Instrument 2016/191.

	2023 \$'000	2022 \$'000
<b>Audit services</b>		
Deloitte Touche Tohmatsu		
Audit of financial reports	564 <sup>1</sup>	446
<b>Other assurance and non-assurance services</b>		
Statutory assurance services required by legislation to be provided by the auditor	95 <sup>2</sup>	75
Other non-assurance services	112	169
	<b>771</b>	<b>690</b>

<sup>1</sup>Includes fees for prior year services of \$68 000

<sup>2</sup>Includes fees for prior year services of \$20 000

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 14. Events occurring after the reporting period

### Overview

AASB 110 *Events after the reporting period* requires disclosure when material events occur between the balance date and the date the financial accounts are authorised for issue. It includes events that may require changes to the financial statements, or which may mean the Company should not prepare its financial statements on a going concern basis, or events which need disclosure to fully understand the Company's situation.

### Retirement Reward Plan

Having considered the financial position and projected outlook for Avant, the Board resolved to notionally contribute a further \$30,000,000 to the RRP in respect of the year ended 30 June 2023.

In addition, at that meeting, the Board also resolved to determine dividends and authorise payments for Retirement Reward Dividends totalling \$15,800,000 to eligible retiring members. This represents the ninth time dividends were determined under the RRP, and this continues the tradition of being the first medical defence organisation in Australia to pay fully franked dividends to members.

### myBeepr

Prior to 30 June 2023 the Board made a decision to cease further investment into myBeepr. Subsequent to the end of the year, processes commenced for the orderly wind down for an expected immaterial cost to the Group.

No other matter or circumstance has arisen since 30 June 2023 that has significantly affected or may significantly affect:

- i. the operations of the Company in future financial years, or
- ii. the results of those operations in future financial years, or
- iii. the state of affairs of the Company in future financial years

## Note 15. Contingent liabilities

### Overview

Contingent liabilities are disclosed when the possibility of a future settlement of economic benefits is considered less than probable but more likely than remote. If the expected settlement of the liability becomes probable, a provision is recognised.

In the normal course of business, the Group is exposed to contingent liabilities in relation to claims litigation arising out of its insurance transactions and may be exposed to the possibility of contingent liabilities in relation to non-insurance litigation. Where items of this nature are known to exist, a provision would be made for amounts that are both probable and quantifiable. At year end, no material items of this nature are known to exist.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 16. Summarised company financial information

#### Overview

The *Corporations Act 2001* requires the disclosure of summarised financial information for the ultimate parent entity, Avant Mutual Group Limited.

#### Statement of comprehensive income:

	2023 \$'million	2022 \$'million
Earned membership subscription revenues and fees	44.5	42.1
Dividends from subsidiary	14.4	11.1
Director related costs	(1.2)	(1.2)
General & administration expenses	(35.8)	(28.2)
Other income	5.5	2.5
<b>Profit before income tax</b>	<b>27.4</b>	<b>26.3</b>
Income tax benefit	-	0.1
<b>Profit for the year</b>	<b>27.4</b>	<b>26.4</b>
Other comprehensive income for the year	-	-
<b>Total comprehensive income for the year</b>	<b>27.4</b>	<b>26.4</b>

#### Statement of financial position:

##### Current assets

Cash at bank	3.3	1.9
Receivables from related entities	36.0	58.7
Other receivables	17.7	18.3
<b>Total current assets</b>	<b>57.0</b>	<b>78.9</b>

##### Non-current assets

Investments in controlled entities	579.6	561.6
<b>Total non-current assets</b>	<b>579.6</b>	<b>561.6</b>

##### Current liabilities

Current tax liabilities	2.5	25.9
Payables to related entities	5.3	1.9
Other payables	3.3	2.5
Unearned income	32.7	30.4
<b>Total current liabilities</b>	<b>43.8</b>	<b>60.7</b>

<b>Net assets</b>	<b>592.8</b>	<b>579.8</b>
-------------------	--------------	--------------

##### Equity

Reserves	508.6	508.6
Accumulated surpluses	84.2	71.2
<b>Total equity</b>	<b>592.8</b>	<b>579.8</b>

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 17. Investments in controlled entities

### Overview

This section lists all of the Group's controlled entities. The consolidated financial statements incorporate the assets and liabilities of all entities controlled by the Company as at 30 June 2023 and the results for the financial year then ended, or for the period during which control existed if the entity was acquired or disposed of during the financial year.

### How we account for the numbers

Control exists when the Group is exposed or has rights to variable returns from its involvement with an entity and has the ability to affect those returns through its power over it. All transactions between controlled entities are eliminated in full.

Where control of an entity commences during a financial year, its results are included in the consolidated statement of comprehensive income from the date on which control is obtained. Where control of an entity ceases during a financial year, its results are included for that part of the year during which the control existed.

A change in ownership of a controlled entity without the gain or loss of control is accounted for as an equity transaction.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Note 17. Investments in controlled entities (continued)

Name of Entity	Country of incorporation	Class of shares	Ownership Interest	
			2023 %	2022 %
Avant Group Holdings Limited <sup>1</sup>	Australia	-	-	-
The Medical Defence Association of Victoria Limited <sup>1</sup>	Australia	Ordinary	100	100
<b>Investments in controlled entities of Avant Group Holdings Limited</b>				
Avant Insurance Limited	Australia	Ordinary	100	100
The Doctors' Health Fund Pty Ltd	Australia	Ordinary	100	100
The Medical Defence Union Pty Ltd	Australia	Ordinary	100	100
United Medical Protection Pty Limited <sup>2</sup>	Australia	-	-	-
Doctors Financial Services Pty Limited	Australia	Ordinary	100	100
Avant Services Co. Pty Limited	Australia	Ordinary	100	100
MyPracticeManual Pty Ltd	Australia	Ordinary	100	100
Avant Foundation Limited <sup>3</sup>	Australia	-	-	-
KA JV Pty Ltd <sup>4</sup>	Australia	Ordinary	100	55
AK Warehouse Pty Limited <sup>5</sup>	Australia	Ordinary	50	50
Avant Law Pty Ltd <sup>6</sup>	Australia	Ordinary	100	100
<b>Investments in controlled entities of KA JV Pty Ltd</b>				
AK Warehouse Pty Limited	Australia	Ordinary	50	50
KA JV 2 Pty Ltd	Australia	Ordinary	100	100
<b>Investments in controlled entities of MyPracticeManual Pty Ltd</b>				
Darjack Pty Limited	Australia	Ordinary	100	60
JRB Technologies Pty Ltd	Australia	Ordinary	55	55
HMPM Pty Ltd <sup>7</sup>	Australia	Ordinary	100	20
<b>Investments in controlled entities of Avant Insurance Limited</b>				
Avant Law Pty Limited <sup>6</sup>	Australia	Ordinary	-	-
<b>Investments in controlled entities of Avant Law Pty Limited</b>				
Avant Law (SA) Pty Limited <sup>8</sup>	Australia	Ordinary	-	100
<b>Investments in controlled entities of The Medical Defence Union Pty Ltd</b>				
Professional Insurance Australia Pty Ltd <sup>9</sup>	Australia	Ordinary	100	100
<b>Investments in controlled entities of Doctors Financial Services Pty Limited</b>				
Avant Financial Services Pty Ltd <sup>10</sup>	Australia	Ordinary	100	-

<sup>1</sup> Avant Mutual Group Limited does not have any equity interests in this company as it is a member-based entity limited by guarantee. Control is exercised by virtue of the directors of Avant Group Holdings Limited sitting on the Board of this entity.

<sup>2</sup> Avant Group Holdings Limited does not have any equity interests in this company as it is a member-based entity limited by guarantee. Control is exercised by virtue of the directors of Avant Group Holdings Limited sitting on the Board of this entity.

<sup>3</sup> Avant Group Holdings Limited has 100% voting control.

<sup>4</sup> Avant Group Holdings Limited acquired the remaining 45% of voting control of KA JV Pty Ltd during the year.

<sup>5</sup> AK Warehouse Pty Limited was incorporated on 3 February 2022. Avant Group Holdings Limited and KA JV each owns 50% of its shareholding.

<sup>6</sup> During the year AIL transferred its holding of 1 share in Avant Law Pty Limited to AGHL.

<sup>7</sup> MyPracticeManual Pty Ltd owned 20% of HMPM Pty Ltd in the previous financial year and accounted it as an associate. During the year the Group increased its interest in Hoxton to 100%, and is now accounted for as a 100% subsidiary of the Group.

<sup>8</sup> Avant Law Pty Ltd's wholly owned subsidiary, Avant Law (SA) Pty Ltd, ABN 87 611 994 042, was deregistered on 14 April 2023.

<sup>9</sup> PIA assets and liabilities were transferred to AIL on 13 April 2022 pursuant to a Federal Court approved scheme and the general insurance licence was revoked on 28 June 2022.

<sup>10</sup> DFS' wholly owned subsidiary, Avant Financial Services Pty Ltd, ABN 92 661 582 270 (AFS), was deregistered on 16 July 2023.

# Notes to the consolidated financial statements

For the year ended 30 June 2023

## Note 18. Related parties

### Key management personnel remuneration

Key management personnel (KMP) and disclosure of their remuneration can be found in note 12.

### Transactions with key management personnel

Some key management personnel are policyholders or customers of the Group. They purchase products and services on the same terms and conditions available to other members and customers, including applicable discounts for Avant Group staff.

The Avant Corporate Travel Insurance policy automatically covers directors, key management personnel, their spouses and dependents for leisure travel more than 500 kilometres from their home.

### Group structure

Up to 30 June 2023, the ultimate Australian parent entity within the Group was Avant Mutual Group Limited. Refer to Note 17 for the details and ownership interests of the controlled entities of the Company up to 30 June 2023.

### Intercompany capital undertakings

As part of a group-wide initiative to centrally manage capital, the Group agreed to support capital undertakings from AGHL to ALL of \$215,000,000 and to DHF of \$17,000,000 in the event that the entities' regulatory capital adequacy multiple falls below a minimum ratio of 1.5.

### Related-party transactions

All transactions and balances remaining between the parties were at arm's length and consisted of the following:

	2023 \$000	2022 \$000
<b>Operating expenses</b>		
Associates	-	21
<b>Dividend received</b>		
Associates (recognised as a reduction in investment in associates)	1,560	1,979

### Other

#### *Insurance Council of Australia*

Avant Insurance Limited, a wholly-owned subsidiary of the Company is a member of the Insurance Council of Australia and the Managing Director is the Group's nominated representative on the ICA's Board. No fees are received by the Managing Director for this Board representation.

#### *HAMBS*

Mr Peter Aroney, CEO of DHF is a director of HAMBS. HAMBS is a mutual organisation and its Board consists of other members of the organisation. HAMBS provides the main software that supports DHF operations. Mr Aroney does not receive payment for his services as a director.

#### *Members Health Fund Alliance*

The Members Health Fund Alliance (MHFA) is the peak industry body of which DHF is one of 26 members. Peter Aroney is one of MHFA's directors.

#### *Challenger Limited*

Challenger Limited is a related entity of the Company. Mr Duncan West, a director of the Company, is the Chairman of Challenger Limited. Mr Anthony Bofinger, a director of the Company, is the Chief Risk Officer of Challenger Limited and is a key management personnel of related entities of Challenger Limited. Mr Peter Polson, a Director of the Company, was a director of Challenger Limited during the year. The Company has investments that are managed indirectly by related entities of

Challenger Limited on an arm's length basis.

#### *Frontier*

Frontier Advisors Pty Ltd (Frontier) is a related entity of the Group. A close family member of a Director of the Company is a key management personnel of Frontier. The Group obtained advisory services from Frontier on an arm's length basis.

# Notes to the consolidated financial statements

## For the year ended 30 June 2023

### Directors' declaration

In the Directors' opinion:

- a) the financial statements and notes set out on pages 8 to 63 are in accordance with the *Corporations Act 2001*, including:
  - i. complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements; and
  - ii. giving a true and fair view of the Company's and Group's financial position as at 30 June 2023 and of their performance for the financial year ended on that date; and
- b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.
- c) Note 1(b) confirms that the financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board.

This declaration is made in accordance with a resolution of the Directors made pursuant to s.295(5) of the *Corporations Act 2001*.



**Dr Beverley Rowbotham AO**  
Chair  
Sydney  
5 September 2023



Deloitte Touche Tohmatsu  
ABN 74 490 121 060

Quay Quarter Tower  
50 Bridge Street  
Sydney NSW 2000 Australia  
PO Box N250  
Sydney NSW 1220 Australia

Phone: +61 2 9322 7000  
[www.deloitte.com.au](http://www.deloitte.com.au)

## Independent Auditor's Report to the Members of Avant Mutual Group Limited

### *Opinion*

We have audited the financial report of Avant Mutual Group Limited (the "Company") and its subsidiaries (the "Group") which comprises the consolidated statement of financial position as at 30 June 2023, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

- giving a true and fair view of the Group's financial position as at 30 June 2023 and of its financial performance for the year then ended; and
- complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

### *Basis for Opinion*

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### *Other Information*

The directors are responsible for the other information. The other information comprises the information included in the Directors' report included in the annual financial report ended 30 June 2023, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed,

Liability limited by a scheme approved under Professional Standards Legislation.  
Member of Deloitte Asia Pacific Limited and the Deloitte organisation.

## Deloitte

we conclude that there is a material misstatement of this other information, we require to report that fact. We have nothing to report in this regard.

### *Responsibilities of the Directors for the Financial Report*

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

### *Auditor's Responsibilities for the Audit of the Financial Report*

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the financial report. We are responsible for the direction, supervision and performance of the Group's audit. We remain solely responsible for our audit opinion.

# Deloitte.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

*Deloitte Touche Tohmatsu*

DELOITTE TOUCHE TOHMATSU



Stuart Alexander  
Partner  
Chartered Accountants  
Sydney, 5 September 2023

**THIS PAGE INTENTIONALLY LEFT BLANK**

**THIS PAGE INTENTIONALLY LEFT BLANK**

# Contact us

## Australian Capital Territory

Unit 10, George Turner House,  
11 McKay Gardens  
Turner ACT 2612

Telephone 03 9026 5961  
Fax 03 8673 5015

## New South Wales

Level 6, Darling Park 3,  
201 Sussex Street  
Sydney NSW 2000

PO Box 746,  
Queen Victoria Building NSW 1230

Telephone 02 9260 9000  
Fax 02 9261 2921

## Queensland

Level 18, 345 Queen Street  
Brisbane QLD 4000

GPO Box 5252,  
Brisbane QLD 4001

Telephone 07 3309 6800  
Fax 07 3309 6850

## South Australia

Level 1, 195 Melbourne Street  
North Adelaide SA 5006

PO Box 1263,  
Adelaide SA 5001

Telephone 08 7071 9800  
Fax 08 7071 5250

## Tasmania

Suite 4, 147 Davey Street  
Hobart TAS 7000

PO Box 895,  
Hobart TAS 7001

Telephone 03 6223 5400  
Fax 1800 228 268

## Victoria

Level 36, Melbourne Central Tower,  
360 Elizabeth Street  
Melbourne VIC 3000

GPO Box 1606,  
Melbourne VIC 3001

Telephone 03 9026 5900  
Fax 03 8673 5015

## Western Australia

Level 1, Schiavello,  
1315 Hay Street  
West Perth WA 6005

PO Box 950,  
West Perth WA 6872

Telephone 08 6189 5700  
Fax 08 6189 5713

[avant.org.au](http://avant.org.au) | 1800 128 268

Avant Mutual Group Limited ABN 58 123 154 898

10/23 (DT-3469)